



Optum Epidemiology publications

Peer-reviewed, by therapeutic area

Cardiovascular

Wong HL, Hu M, Zhou CK, Lloyd P, **Amend KL**, Beachler D, Secora A, McMahonill-Walraven CN, Lu Y, Wu Y, **Ogilvie, RP**, Reich C, Djibo DA, Wan Z, **Seeger JD**, Akhtar S, Jiao Y, Chillarige Y, Do R, Hornberger J, Obidi J, Forshee R, Shoaibi A, Anderson SA. Risk Of Myocarditis/ Pericarditis Following COVID-19 mRNA Vaccination in the United States: A Cohort Study In Claims Databases. *Lancet*. 2022 Jun 11;399(10342):2191-2199.

Hoffman V, Hallas J, Linder M, Margulis AV, Suehs BT, Arana A, **Phiri K**, **Enger C**, Horter L, Odsbu I, Olesen M, Perez-Gutthann S, Xu Y, Kristiansen NS, Appenteng K, de Vogel S, **Seeger JD**, et al. Cardiovascular risk in users of mirabegron compared with users of antimuscarinic treatments for overactive bladder: Findings from a non-interventional, multinational, cohort study. *Drug Saf*. 2021 Aug;44(8):899-915.

Hoffman V, Xue F, **Ezzy SM**, Yusuf A, Green E, Eisele O, Kurth T, **Seeger JD**. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine receiving prophylactic treatments: An observational cohort study. *Cephalalgia*. 2019 Oct;39(12):1544-1559.

Sabin JE, Cocoros NM, Garcia CJ, Goldsack JC, Haynes K, **Lin ND**, et al. Bystander ethics and good samaritanism: A paradox for learning health organizations. *Hastings Center Report*. 2019 Aug 20;49(4):18-26.

Nunes AP, Igly K, Radican L, Engel SS, **Yang J**, **Doherty MC**, et al. Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. *Diabetes Obes Metab*. 2017 Oct;19(10):1425-1435.

Yih WK, Greene SK, Zichittella L, Kulldorff M, Baker MA, de Jong JL, Gil-Prieto R, Griffin MR, Jin R, **Lin ND**, et al. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among U.S. females. *Vaccine*. 2016 Jan 2;34(1):172-8.

Walker AM, **Liang C**, **Clifford CR**, Parker C, Feldman A. Cardiac mortality in users of olmesartan, other angiotensin-receptor blockers and angiotensin-converting enzyme inhibitors. *Pharmacoepidemiol Drug Saf*. 2014 Apr;23(4):348-56.

Thyagarajan V, **Clifford CR**, Wurst KE, Ephross SA, **Seeger JD**. Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. *Pharmacoepidemiol Drug Saf*. 2012 Nov;21(11):1240-2.

Xue F, Strombom I, **Turnbull B**, **Zhu S**, **Seeger J**. Treatment with duloxetine in adults and the incidence of cardiovascular events. *J Clin Psychopharmacol*. 2012 Feb;32(1):23-30.

Wang S, Linkletter C, **Dore D**, Mor V, Buka S, Maclure M. Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. *Stroke*. 2012 Jan;43(1):28-31.

Habel LA, Cooper WO, Sox CM, **Chan KA**, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA*. 2011;306(24):2673-83.

Cooper WO, Habel LA, Sox CM, **Chan KA**, Arbogast PG, Cheetham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. *N Engl J Med*. 2011;365(20):1896-904.

Amend KL, **Landon J**, **Thyagarajan V**, Niemcryk S, **McAfee A**. Incidence of hospitalized rhabdomyolysis with statin and fibrates use in an insured U.S. population. *Ann Pharmacother*. 2011 Oct;45(10):1230-9.

Carman WJ, **Su S**, Cook SF, Wurzelmann JI, **McAfee A**. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. *Pharmacoepidemiol Drug Saf*. 2011 Jul;20(7):754-62.

Enger C, **Gately R**, Ming EE, Niemcryk SJ, Williams L, **McAfee AT**. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. *Am J Cardiol*. 2010 Dec;106(11):1594-601.

Loughlin J, **Quinn S**, Rivero E, **Wong J**, Huang J, Kralstein J, et al. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. *J Cardiovasc Pharmacol Ther*. 2010 Jun;15(2):151-7.

- Dore DD, Norman H, Loughlin J, Seeger JD.** Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. *Contraception*. 2010 May;81(5):408-13.
- Ziyadeh N, McAfee AT, Koro C, Landon J, Chan KA.** The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a U.S. health insurance database. *Clin Ther*. 2009 Nov;31(11):2665-77.
- Holick CN, Turnbull BR, Jones ME, Chaudhry S, Bangs ME, Seeger JD.** Atomoxetine and cerebrovascular outcomes in adults. *J Clin Psychopharmacol*. 2009 Oct;29(5):453-60.
- Dore DD, Norman H, Seeger JD.** Eligibility criteria in venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. *Obstet Gynecol*. 2009 Jul;114(1):175.
- Dore DD, Trivedi AN, Mor V, Lapane KL.** Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. *Pharmacotherapy*. 2009 Jul;29(7):775-83.
- Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA.** Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. *Ann Intern Med*. 2009 Jan 6;150(1):9-18.
- Schneeweiss S, **Seeger JD, Landon J, Walker AM.** Aprotinin during coronary-artery bypass grafting and risk of death. *N Engl J Med*. 2008;358(8):771-83.
- Loughlin J, Seeger JD, Eng PM, Foegh M, Clifford CR, Cutone J, et al.** Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. *Contraception*. 2008 Nov;78(5):377-83.
- Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM.** Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. *Pharmacoepidemiol Drug Saf*. 2008 Mar;17(3):297-305.
- Valentgas P, Sheffield R, Nordstrom B, Johnson E, Do T, Mentor SM, et al.** Persistence with medications in glaucoma management, hypertension, and dyslipidemia. *J Pharm Technol*. 2007;23(4):221-31.104.
- Flick ED, Habel LA, **Chan KA, Van Den Eeden SK, Quinn VP, Haque R, et al.** Statin use and risk of prostate cancer in the California Men's Health Study cohort. *Cancer Epidemiol Biomarkers Prev*. 2007 Nov;16(11):2218-25.
- Seeger JD, Loughlin J, Eng PM, Clifford CR, Cutone J, Walker AM.** Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. *Obstet Gynecol*. 2007 Sep;110(3):587-93.
- McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.** Coronary heart disease outcomes in patients receiving antidiabetic agents. *Pharmacoepidemiol Drug Saf*. 2007 Jul;16(7):711-25.
- Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.** The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. *Pharmacoepidemiol Drug Saf*. 2007 May;16(5):504-12.
- Mona Eng P, Seeger JD, Loughlin J, Oh K, Walker AM.** Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. *Contraception*. 2007 Feb;75(2):101-7.
- Cole JA, Norman H, Doherty M, Walker AM.** Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. *Obstet Gynecol*. 2007 Feb;109(2 Pt 1):339-46.
- Lin ND, Martins SB, Chan AS, Coleman RW, Bosworth HB, Oddone EZ, et al.** Identifying barriers to hypertension guideline adherence using clinician feedback at the point of care. *AMIA Annu Symp Proc*. 2006; 2006:494-498.
- Walker AM, Schneider G, Yeaw J, Nordstrom B, Robbins S, Pettitt D.** Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. *J Am Soc Nephrol*. 2006;17(8):2293-8.
- Johansson S, Ming EE, Wallander MA, Rodriguez LA, Herings RM, Goettsch WG, **McAfee AT, Walker AM.** Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. *Pharmacoepidemiol Drug Saf*. 2006;15(7):454-61.
- Valentgas P, West W, Cannuscio CC, Watson DJ, Walker AM.** Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. *Pharmacoepidemiol Drug Saf*. 2006 Sep;15(9):641-52.
- Caron MF, **Dore DD, Min B, Kluger J, Boguk I, White CM.** Electrocardiographic and blood pressure effects of the ephedra-containing TrimSpa thermogenic herbal compound in healthy volunteers. *Pharmacotherapy*. 2006 Sep;26(9):1241-6.
- Cole JA, Norman H, Weatherby LB, Walker AM.** Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. *Pharmacotherapy*. 2006 Aug;26(8):1157-64.
- McAfee AT, Ming EE, Seeger JD, Quinn SG, Ng EW, Danielson JD, et al.** The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. *Pharmacoepidemiol Drug Saf*. 2006 Jul;15(7):444-53.
- Valentgas P, Cole JA, Mo J, Sikes CR, **Walker AM.** Severe vascular events in migraine patients. *Headache*. 2004 Jul-Aug;44(7):642-51.
- Enger C, Weatherby L, Reynolds RF, Glasser DB, Walker AM.** Serious cardiovascular events and mortality among patients with schizophrenia. *J Nerv Ment Dis*. 2004 Jan;192(1):19-27.
- Seeger JD, Walker AM, Williams PL, Saperia GM, Sacks FM.** A propensity score-matched cohort study of the effect of statins, mainly fluvastatin, on the occurrence of acute myocardial infarction. *Am J Cardiol*. 2003 Dec;92(12):1447-51.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, **Walker AM**, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. *Clin Pharmacol Ther*. 2003 Oct;74(4):388-400.

Kurth T, Glynn RJ, **Walker AM**, Chan KA, Buring JE, Hennekens CH, et al. Inhibition of clinical benefits of aspirin on first myocardial infarction by nonsteroidal antiinflammatory drugs. *Circulation*. 2003 Sep 9;108(10):1191-5.

Eng PM, Fitzmaurice G, Kubzansky LD, Rimm EB, Kawachi I. Anger expression and risk of stroke and coronary heart disease among male health professionals. *Psychosom Med*. 2003 Jan-Feb;65(1):100-10.

Eng PM, Rimm EB, Fitzmaurice G, Kawachi I. Social ties and change in social ties in relation to subsequent total and cause-specific mortality and coronary heart disease incidence in men. *Am J Epidemiol*. 2002;155(8):700-9.

Seeger JD. Causal structures for evaluating statin class effects. *Ann Pharmacother*. 2002 Dec;36(12):1961-5.

Enger C, Cali C, **Walker AM**. Serious ventricular arrhythmias among users of cisapride and other QT-prolonging agents in the United States. *Pharmacoepidemiol Drug Saf*. 2002 Sep;11(6):477-86.

Kaye JA, Meier CR, **Walker AM**, Jick H. Statin use, hyperlipidaemia, and the risk of breast cancer. *Br J Cancer*. 2002 May 6;86(9):1436-9.

Lauer MA, Karweit JA, Cascade EF, **Lin ND**, Topol EJ. Practice patterns and outcomes of percutaneous coronary interventions in the United States: 1995 to 1997. *Am J Cardiol*. 2002 Apr 15;89(8):924-9.

Schneeweiss S, **Walker AM**, Glynn RJ, Maclure M, Dormuth C, Soumerai SB. Outcomes of reference pricing for angiotensin-converting-enzyme inhibitors. *N Engl J Med*. 2002 Mar;346(11):822-9.

Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, **Walker AM**. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. *CMAJ*. 2002 Mar 19;166(6):737-45.

Chong PH, **Seeger JD**, Franklin C. Clinically relevant differences between the statins: implications for therapeutic selection. *Am J Med*. 2001 Oct 1;111(5):390-400.

Rich S, Rubin L, **Walker AM**, Schneeweiss S, Abenham L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. *Chest*. 2000 Mar;117(3):870-4.

COVID-19

Hu M, Wong HL, Feng Y, Lloyd PC, Smith ER, **Amend KL**, Kline A, Beachler DC, Gruber JF, Mitra M, **Seeger JD**, Harris C, Secora A, Obidi J, Wang J, **Song J**, McMahill-Walraven CN, Reich C, McEvoy R, Do R, Chillarige Y, **Clifford CR**, Cooper DD, Shoaibi A, Forshee R, Anderson SA. Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine U.S. children aged 5-17 years: a cohort study of vaccine safety. Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years. *JAMA Pediatr*. Published online May 22, 2023.

Schneider KL, **Bell EJ**, Zhou CK, Grace Yang, Lloyd PC, Clarke TC, **Wilkinson M**, Myers EE, **Amend KL**, **Seeger JD**, Chillarige Y, Forshee R, Shoaibi A, Anderson SA, Wong HL. Immunization Information Systems to Improve Ascertainment of COVID-19 Vaccinations for Claims-based Vaccine Safety and Effectiveness Studies. *JAMA Network Open*. 2023;6(5):e2313512.5.

Moll K, Lufkin B, Fingar KR, Zhou CK, Tworokski E, Shi C, Hobbi S, Hu M, Sheng M, McCarty J, Shangguan S, Burrell T, Chillarige Y, Beers J, Saunders-Hastings P, Edwards K, Muthuri S, Black S, Kelman J, Reich C, **Amend KL**, Djibo A, Beachler D, **Ogilvie RP**, Secora A, McMahill-Walraven CN, **Seeger JD**, Lloyd P, Thompson D, Dimova R, MaCurdy T, Obidi J, Anderson S, Forshee R, Wong HL, Shoaibi A. Background rates of adverse events of special interest for COVID-19 vaccine safety monitoring in the United States, 2019-2020. *Vaccine*. 2023 Jan 9;41(2):333-353.

Wong HL, Hu M, Zhou CK, Lloyd P, **Amend KL**, Beachler D, Secora A, McMahill-Walraven CN, Lu Y, Wu Y, **Ogilvie, RP**, Reich C, Djibo DA, Wan Z, **Seeger JD**, Akhtar S, Jiao Y, Chillarige Y, Do R, Hornberger J, Obidi J, Forshee R, Shoaibi A, Anderson SA. Risk of Myocarditis/ Pericarditis Following COVID-19 mRNA Vaccination in the United States: A Cohort Study in Claims Databases. *Lancet*. 2022 Jun 11;399(10342):2191-2199.

Liang C, **Ogilvie RP**, **Doherty MC**, **Clifford CR**, **Chomistek AK**, **Gately RV**, **Song JN**, **Enger C**, **Seeger JD**, Lin N, **Wang FT**. Trends in COVID-19 Patient Characteristics in a Large Electronic Health Record Database in the United States. *PLOS ONE*. 2022 Jul 20. 17(7), e0271501.

Chomistek AK, **Liang C**, **Doherty MC**, **Clifford CR**, **Ogilvie RP**, **Gately RV**, **Song JN**, **Enger C**, Lin N.D., **Wang FT**, **Seeger JD**. Predictors of Critical Care, Mechanical Ventilation, and Mortality among Hospitalized Patients with COVID-19 in an Electronic Health Record Database. *BMC Infectious Diseases*. 2022 Apr;22(1):413.

Lloyd P, Hu M, Wong HL, Shoaibi A, Zhou C, Lo AC, **Amend KL**, Beachler D, McMahill-Walraven C, Smith E, **Seeger JD**, Secora A, Djibo A, Obidi J, Feng Y, **Song J**, Reich C, Harris C, Akhtar S, **Clifford CR**, Selvam N, Pigoga J, Jiao Y, Chillarige Y, MaCurdy T, Forshee R, Anderson S. Near Real-Time Surveillance of Safety Outcomes in U.S. COVID-19 Vaccine Recipients aged 12 to 64 years. *Vaccine*. 2022 Oct 26;40(45):6481-6488.

Dermatology

Nunes AP, Lapane KL, Weinstock MA, Group VT. Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. *Pharmacoepidemiol Drug Saf*. 2011 Sept;20(9):922-9.

Ziyadeh N, Fife D, **Walker AM**, **Wilkinson GS**, **Seeger JD**. A matched cohort study of the risk of cancer in users of becaplermin. *Adv Skin Wound Care*. 2011 Jan;24(1):31-9.

Schneeweiss S, **Doherty M**, **Zhu S**, **Funch D**, Schlienger RG, Fernandez-Vidaurre C, et al. Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. *Dermatology*. 2009;219(1):7-21.

Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA. Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. *Ann Intern Med*. 2009 Jan 6;150(1):9-18.

Seeger JD, Lanza LL, West WA, Fernandez C, Rivero E. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. *Dermatology*. 2007;214(1):32-9.

Nordstrom BL, Oh K, Sacks ST, L'Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. *Antivir Ther*. 2004 Apr;9(2):187-95.

Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, et al. EGF gene polymorphism and the risk of incident primary melanoma. *Cancer Res*. 2004 Apr;64(8):2668-72.

Drug utilization and adherence

Kesselheim AS, Sinha MS, Rausch P, Lu Z, Tessema FA, Lappin BM, Zhou EH, Dal Pan GJ, Zwanziger L, Ramanadham A, **Loughlin A, Enger C**, et al. Patients' knowledge of key messaging in drug safety communications for zolpidem and eszopiclone: A national survey. *J Law Med Ethics*. 2019 Sep;47(3):430-441.

Sarpawari A, **Gagne JJ**, Lu Z, Campbell EG, **Carman WJ, Enger C**, et al. A survey of patient's perceptions of pill appearance and responses to changes in appearance for four chronic disease medications. *J Gen Intern Med*. 2019 Mar;34(3):420-428.

Hoffman V, Xue F, Gardstein B, **Skerry K**, Critchlow CW, **Enger C**. Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data. *Osteoporos Int*. 2016 Apr;27(4):1653-8.

Wang FT, Mast TC, Glass RJ, Loughlin J, **Seeger JD**. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. *Pediatr Infect Dis J*. 2013 Mar;32(3):278-83.

Green MW, **Seeger JD**, Peterson C, Bhattacharyya A. Utilization of topiramate during pregnancy and risk of birth defects. *Headache*. 2012 Jul-Aug;52(7):1070-84.

Dore DD, Turnbull BR, Seeger JD. Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. *Pharmacoepidemiol Drug Saf*. 2012 Apr;21(4):415-9.

Funch D, Norman H, Wong J, Bennett R, Hillier J, Al-Sabbagh A, et al. Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records – the RETRO study. *Pharmacoepidemiol Drug Saf*. 2010 May;19(5):448-56.

Mona Eng P, Seeger JD, Loughlin J, Oh K, Walker AM. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. *Contraception*. 2007 Feb;75(2):101-7.

Lin ND, Martins SB, Chan AS, Coleman RW, Bosworth HB, Oddone EZ, et al. Identifying barriers to hypertension guideline adherence using clinician feedback at the point of care. *AMIA Annu Symp Proc*. 2006;2006:494-498.

Lin ND, Kleinman K, Chan KA, Yu X-J, France EK, Wei F, et al. Variation in hepatitis B immunization coverage rates associated with provider practices after the temporary suspension of the birth dose. *BMC Pediatrics*. 2006 Nov;6(1):31.

Cole JA, Norman H, Weatherby LB, Walker AM. Drug copayment and adherence in chronic heart failure: effect on cost and outcomes. *Pharmacotherapy*. 2006 Aug;26(8):1157-64.

Lin ND, Kleinman K, **Chan KA**, Yu XJ, France EK, Xu S, et al. Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants. *BMC Pediatr*. 2005 Nov;5:43.

Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, **Walker AM**. Persistence and adherence with topical glaucoma therapy. *Am J Ophthalmol*. 2005 Oct;140(4):598-606.

Turnbull BR, Zoutman DE, Lam M. Evaluation of hospital and patient factors that influence the effective administration of surgical antimicrobial prophylaxis. *Infect Control Hosp Epidemiol*. 2005 May;26(5):478-85.

Schneeweiss S, Soumerai SB, Maclure M, Dormuth C, **Walker AM**, Glynn RJ. Clinical and economic consequences of reference pricing for dihydropyridine calcium channel blockers. *Clin Pharmacol Ther*. 2003 Oct;74(4):388-400.

Weatherby LB, Nordstrom BL, Fife D, **Walker AM**. The impact of wording in "Dear doctor" letters and in black box labels. *Clin Pharmacol Ther*. 2002 Dec;72(6):735-42.

Loughlin JE, Cole JA, Dodd SL, Schein JR, Thornhill JC, **Walker AM**. Comparison of resource utilization by patients treated with transdermal fentanyl and long-acting oral opioids for nonmalignant pain. *Pain Med*. 2002 Mar;3(1):47-55.

Schneeweiss S, Soumerai SB, Glynn RJ, Maclure M, Dormuth C, **Walker AM**. Impact of reference-based pricing for angiotensin-converting enzyme inhibitors on drug utilization. *CMAJ*. 2002 Mar 19;166(6):737-45.

Walker AM. Pattern recognition in health insurance claims databases. *Pharmacoepidemiol Drug Saf*. 2001 Aug-Sep;10(5):393-7.

Weatherby LB, **Walker AM**, Fife D, Vervae P, Klausner MA. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. *Pharmacoepidemiol Drug Saf*. 2001 May;10(3):211-8.

Endocrinology and diabetes

Liang C, Bertoia ML, Ding Y, Clifford CR, Qiao Q, **Gagne JJ, Dore DD**. Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study. *Diabetes Obes Metab*. 2019 Apr;21(4):1037-1042.

Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Li L, Norman H, Major-Pedersen A, Bosch-Traberg H, Gydesen H, **Dore DD**. Liraglutide use and evaluation of pancreatic outcomes in a U.S. commercially insured population. *Diabetes Obes Metab*. 2019;1-12.

- Funch D, Mortimer K, Li L, Norman H, Major-Pedersen A, Olsen AH, Kaltoft MS, Dore DD.** Is there an association between liraglutide use and female breast cancer in a real-world setting? *Diabetes Metab Syndr Obes.* 2018 Nov;11:791-806.
- Loughlin AM, Qiao Q, Nunes AP, Ezzy SM, Yochum L, Clifford CR, Gately RV, Dore DD, Seeger JD.** Effectiveness and tolerability of therapy with once-weekly exenatide versus basal insulin among injectable-naïve patients with Type 2 diabetes in a real-world setting in the United States. *Diabetes Spectr.* 2018 May;31(2):129-137.
- Loughlin AM, Qiao Q, Nunes AP, Ohman P, Ezzy S, Yochum L, et al.** Effectiveness and tolerability of therapy with exenatide once weekly vs. basal insulin among injectable-drug-naïve elderly or renal impaired patients with Type 2 diabetes in the United States. *Diabetes Obes Metab.* 2018 Apr;20(4):898-909.
- Funch D, Ross D, Gardstein BM, Norman HS, Sanders LA, Major-Pedersen A, et al.** Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies. *BMC Health Serv Res.* 2017;17:330.
- Nunes AP, Loughlin AM, Qiao Q, Ezzy SM, Yochum L, Clifford CR, et al.** Tolerability and effectiveness of exenatide once weekly relative to basal insulin among Type 2 diabetes patients of different races in routine care. *Diabetes Ther.* 2017 Dec;8(6):1349-1364.
- Nunes AP, Iglay K, Radican L, Engel SS, Yang J, Doherty MC, et al.** Hypoglycaemia seriousness and weight gain as determinants of cardiovascular disease outcomes among sulfonylurea users. *Diabetes Obes Metab.* 2017 Oct;19(10):1425-1435.
- Nunes AP, Yang J, Radican L, Engel SS, Kurtyka K, Tunceli K, et al.** Assessing occurrence of hypoglycemia and its severity from electronic health records of patients with Type 2 diabetes mellitus. *Diabetes Res Clin Pract.* 2016 Nov;121:192-203.
- Zarotsky V, Huang MY, **Carman W**, Morgentaler A, Singhal PK, Coffin D, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. *Andrology.* 2014 Nov;2(6):819-34.
- Funch D, Gydesen H, Tornoe K, Major-Pedersen A, Chan KA.** A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. *Diabetes Obes Metab.* 2014 Mar;16(3):273-5.
- Enger C, Jones ME, Kryzhanovskaya L, Doherty M, McAfee AT.** Risk of developing diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia. *Int J Adolesc Med Health.* 2013;25(1):3-11.
- Dore DD, Hussein M, Hoffman C, Pelletier EM, Smith DB, Seeger JD.** A pooled analysis of exenatide use and risk of acute pancreatitis. *Curr Med Res Opin.* 2013 Dec;29(12):1577-86.
- Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al.** A cohort study of acute pancreatitis in relation to exenatide use. *Diabetes Obes Metab.* 2011 Jun;13(6):559-66.
- Dore DD, Chaudhry S, Hoffman C, Seeger JD.** Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. *Pharmacoepidemiol Drug Saf.* 2011 Feb;20(2):209-13.
- Ziyadeh N, Fife D, Walker AM, Wilkinson GS, Seeger JD.** A matched cohort study of the risk of cancer in users of becapermin. *Adv Skin Wound Care.* 2011 Jan;24(1):31-9.
- Ziyadeh N, McAfee AT, Koro C, Landon J, Arnold Chan K.** The thiazolidinediones rosiglitazone and pioglitazone and the risk of coronary heart disease: a retrospective cohort study using a U.S. health insurance database. *Clin Ther.* 2009 Nov;31(11):2665-77.
- Dore DD, Trivedi AN, Mor V, Lapane KL.** Association between extent of thiazolidinedione exposure and risk of acute myocardial infarction. *Pharmacotherapy.* 2009 Jul;29(7):775-83.
- Dore DD, Seeger JD, Arnold Chan K.** Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. *Curr Med Res Opin.* 2009 Apr;25(4):1019-27.
- McAfee AT, Koro C, Landon J, Ziyadeh N, Walker AM.** Coronary heart disease outcomes in patients receiving antidiabetic agents. *Pharmacoepidemiol Drug Saf.* 2007 Jul;16(7):711-25.
- Johannes CB, Koro CE, Quinn SG, Cutone JA, Seeger JD.** The risk of coronary heart disease in type 2 diabetic patients exposed to thiazolidinediones compared to metformin and sulfonylurea therapy. *Pharmacoepidemiol Drug Saf.* 2007 May;16(5):504-12.
- Kieffer EC, Tabaei BP, **Carman WJ**, Nolan GH, Guzman JR, Herman WH. The influence of maternal weight and glucose tolerance on infant birthweight in Latino mother-infant pairs. *Am J Public Health.* 2006 Dec;96(12):2201-8.
- Zavras AI, Zhu S.** Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? *J Oral Maxillofac Surg.* 2006 Jun;64(6):917-23.
- Reynolds RF, Obermeyer CM, **Walker AM**, Guilbert D. The role of treatment intentions and concerns about side effects in women's decision to discontinue postmenopausal hormone therapy. *Maturitas.* 2002 Nov 20;43(3):183-94.
- Hurley CR, Mishra A, Cantor SE, Nelson M, **Walker AM.** A 'real-world' analysis of persistence on and adherence to glipizide GITS, glipizide IR and glibenclamide in managed care among patients with type 2 diabetes mellitus. *Clin Drug Investig.* 2002 Sep;22(9):575-84.
- Reynolds RF, **Walker AM**, Obermeyer CM, Rahman O, Guilbert D. Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO. *J Clin Epidemiol.* 2001 Oct;54(10):1056-64.
- Reynolds RF, Obermeyer CM, **Walker AM**, Guilbert D. Side effects and sociobehavioral factors associated with the discontinuation of hormone therapy in a Massachusetts health maintenance organization. *Menopause.* 2001 May-Jun;8(3):189-99.

Gastrointestinal

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. *Pediatr Infect Dis J.* 2013 Mar;32(3):278-83.

Seeger JD, Quinn S, Earnest DL, Lembo A, Kuo B, Rivero E, et al. The Zelnorm epidemiologic study (ZEST): a cohort study evaluating incidence of abdominal and pelvic surgery related to tegaserod treatment. *BMC Gastroenterol.* 2012;12:171.

Eng PM, Mast TC, Loughlin J, Clifford CR, Wong J, Seeger JD. Incidence of intussusception among infants in a large commercially insured population in the United States. *Pediatr Infect Dis J.* 2012 Mar;31(3):287-91.

Dore DD, Bloomgren GL, Wenten M, Hoffman C, Clifford CR, Quinn SG, et al. A cohort study of acute pancreatitis in relation to exenatide use. *Diabetes Obes Metab.* 2011 Jun;13(6):559-66.

Dore DD, Chaudhry S, Hoffman C, Seeger JD. Stratum-specific positive predictive values of claims for acute pancreatitis among commercial health insurance plan enrollees with diabetes mellitus. *Pharmacoepidemiol Drug Saf.* 2011 Feb;20(2):209-13.

Loughlin J, Quinn S, Rivero E, Wong J, Huang J, Kralstein J, et al. Tegaserod and the risk of cardiovascular ischemic events: an observational cohort study. *J Cardiovasc Pharmacol Ther.* 2010 Jun;15(2):151-7.

Wang FT, Mast TC, Glass RJ, Loughlin J, Seeger JD. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. *Pediatrics.* 2010 Feb;125(2):e208-13.

Castellsague J, Holick CN, Hoffman CC, Gimeno V, Stang MR, Perez-Gutthann S. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. *Pharmacotherapy.* 2009 Dec;29(12):1397-407.

Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, et al. Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. *Pharmacoepidemiol Drug Saf.* 2006 Jan;15(1):47-56.

Cole JA, Yeaw JM, Cutone JA, Kuo B, Huang Z, Earnest DL, et al. The incidence of abdominal and pelvic surgery among patients with irritable bowel syndrome. *Dig Dis Sci.* 2005 Dec;50(12):2268-75.

Walker AM, Bohn RL, Cali C, Cook SF, Ajene AN, Sands BE. Risk factors for colon ischemia. *Am J Gastroenterol.* 2004 Jul;99(7):1333-7.

Cole JA, Cook SF, Sands BE, Ajene AN, Miller DP, Walker AM. Occurrence of colon ischemia in relation to irritable bowel syndrome. *Am J Gastroenterol.* 2004 Mar;99(3):486-91.

Miller DP, Alfredson T, Cook SF, Sands BE, Walker AM. Incidence of colonic ischemia, hospitalized complications of constipation, and bowel surgery in relation to use of alosetron hydrochloride. *Am J Gastroenterol.* 2003 May;98(5):1117-22.

Weatherby LB, Walker AM, Fife D, Vervaet P, Klausner MA. Contraindicated medications dispensed with cisapride: temporal trends in relation to the sending of 'Dear Doctor' letters. *Pharmacoepidemiol Drug Saf.* 2001 May;10(3):211-8.

Genetics

Everage NJ, Bai Y, Loop B, Volkova N, Liu N, Enger C. Diagnosed cataracts in patients with cystic fibrosis in a United States administrative database. *Ophthalmic Genet.* 2017 Dec;38(6):527-532.

Amend K, Choi J, Ambrosone C. Role of genetic variability in breast cancer treatment outcomes. In: Leyland-Jones B, editor. *Pharmacogenetics of breast cancer: Towards the individualization of therapy.* 1st ed. New York, NY: Informa Healthcare USA, Inc.;2008:25-43.

Wilcox MA, McAfee AT. Empirically derived subgroups in rheumatoid arthritis: association with single-nucleotide polymorphisms on chromosome 6. *BMC Proc.* 2007;1 Suppl 1:S20.

Wilcox MA, Li Z, Tapper W, Browning S, Curtin K, Ding J, et al. Genetic association with rheumatoid arthritis-genetic analysis workshop 15: summary of contributions from group 2. *Genet Epidemiol.* 2007;31 Suppl 1:S12-21.

Wang FT, Hu H, Schwartz J, Weuve J, Spiro AS, Sparrow D, et al. Modifying effects of the HFE polymorphisms on the association between lead burden and cognitive decline. *Environ Health Perspect.* 2007 Aug;115(8):1210-5.

de Mattos JC, Lage C, Dantas FJ, Moraes MO, Nunes AP, Bezerra RJ, et al. Interaction of stannous chloride leads to alteration in DNA, triphosphate nucleotides and isolated bases. *Mol Cell Biochem.* 2005 Dec;280(1-2):173-9.

Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, et al. EGF gene polymorphism and the risk of incident primary melanoma. *Cancer Res.* 2004 Apr;64(8):2668-72.

Hematology

Wyszynski DF, Carman WJ, Cantor AB, Graham JM, Jr., Kunz LH, Slavotinek AM, et al. Pregnancy and birth outcomes among women with idiopathic thrombocytopenic purpura. *J Pregnancy.* 2016;2016:8297407.

Yih WK, Greene SK, Zichittella L, Kulldorff M, Baker MA, de Jong JL, Gil-Prieto R, Griffin MR, Jin R, Lin ND, et al. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among U.S. females. *Vaccine.* 2016 Jan 2;34(1):172-8.

Enger C, Bennett D, Dawson KL, Aivado MA, Theodore D, McAfee AT. Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP). *Ann Hepatol.* 2011 Apr-Jun;10(2):188-95.

Amend KL, Turnbull B, Foskett N, Napalkov P, Kurth T, Seeger J. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. *Neurology.* 2010 Oct;75(15):1326-32.

Enger C, Bennett D, Forssen U, Fogarty PF, **McAfee AT**. Comorbidities in patients with persistent or chronic immune thrombocytopenia. *Int J Hematol*. 2010 Sep;92(2):289-95.

Dore DD, Norman H, Loughlin J, **Seeger JD**. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. *Contraception*. 2010 May;81(5):408-13.

Schneeweiss S, **Seeger JD**, Landon J, **Walker AM**. Aprotinin during coronary-artery bypass grafting and risk of death. *N Engl J Med*. 2008;358(8):771-83.

Walker AM, Schneider G, Yeaw J, **Nordstrom B**, Robbins S, Pettitt D. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. *J Am Soc Nephrol*. 2006;17(8):2293-8.

Miller DP, Kaye JA, Shea K, **Ziyadeh N**, Cali C, Black C, et al. Incidence of thrombotic thrombocytopenic purpura/hemolytic uremic syndrome. *Epidemiology*. 2004 Mar;15(2):208-15.

Hepatic

Lin ND, Norman H, Regev A, Perahia DG, Li H, Chang CL, et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a U.S. health care claims database. *BMC Gastroenterol*. 2015 Oct 14;15:134.

Blanchette CM, **Nunes AP**, **Lin ND**, **Mortimer KM**, Noone J, Tangirala K, et al. Adherence to risk evaluation and mitigation strategies (REMS) requirements for monthly testing of liver function. *Drugs Context*. 2015 Feb 10;4.

Xue F, Strombom I, **Turnbull B**, **Zhu S**, **Seeger JD**. Duloxetine for depression and the incidence of hepatic events in adults. *J Clin Psychopharmacol*. 2011 Aug;31(4):517-22.

Enger C, Bennett D, Dawson KL, Aivado MA, Theodore D, **McAfee AT**. Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP). *Ann Hepatol*. 2011 Apr-Jun;10(2):188-95.

Pelletier SJ, Fu S, **Thyagarajan V**, Romero-Marrero C, Batheja MJ, Punch JD, et al. An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. *Liver Transpl*. 2009 Aug;15(8):859-68.

Strombom I, Wernicke JF, **Seeger J**, D'Souza DN, Acharya N. Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources. *Curr Drug Saf*. 2008 May;3(2):154-62.

Dore DD, DiBello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. *Drug Saf*. 2007;30(8):697-703.

Hypersensitivity

McCarthy NL, Gee J, **Lin ND**, **Thyagarajan V**, Pan Y, Su S, et al. Evaluating the safety of influenza vaccine using a claims-based health system. *Vaccine*. 2013 Dec 5;31(50):5975-82.

Velentgas P, Amato AA, Bohn RL, **Chan KA**, Cochrane T, **Funch DP**, et al. Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. *Pharmacoepidemiol Drug Saf*. 2012 Dec;21(12):1350-8.

Johannes CB, **Ziyadeh N**, **Seeger JD**, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. *Drug Saf*. 2007;30(8):705-13.

Nordstrom BL, Norman HS, **Dube TJ**, **Wilcox MA**, **Walker AM**. Identification of abacavir hypersensitivity reaction in health care claims data. *Pharmacoepidemiol Drug Saf*. 2007 Mar;16(3):289-96.

Nordstrom BL, **Oh K**, Sacks ST, L'Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. *Antivir Ther*. 2004 Apr;9(2):187-95.

Choi HK, Merkel PA, **Walker AM**, Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. *Arthritis Rheum*. 2000 Feb;43(2):405-13.

Immunology

Baker MA, Jankosky C, Yih WK, Gruber S, Li L, Cocoros NM, Lipowicz H, Coronel-Moreno C, DeLuccia S, **Lin ND**, et al. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines. *Vaccine*. 2020 Feb 24;38(9):2166-2171.

Mast TC, **Wang FT**, Su S, **Seeger JD**. Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States. *Pediatr Infect Dis J*. 2015 Jun;34(6):615-20.

Velentgas P, Amato AA, Bohn RL, **Chan KA**, Cochrane T, **Funch DP**, et al. Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. *Pharmacoepidemiol Drug Saf*. 2012 Dec;21(12):1350-8.

Enger C, Bennett D, Dawson KL, Aivado MA, Theodore D, **McAfee AT**. Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP). *Ann Hepatol*. 2011 Apr-Jun;10(2):188-95.

Amend KL, **Turnbull B**, Foskett N, Napalkov P, **Kurth T**, **Seeger J**. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. *Neurology*. 2010 Oct;75(15):1326-32.

Enger C, Bennett D, Forssen U, Fogarty PF, **McAfee AT**. Comorbidities in patients with persistent or chronic immune thrombocytopenia. *Int J Hematol*. 2010 Sep;92(2):289-95.

Harrold LR, **Patterson MK**, Andrade SE, **Dube T**, Go AS, Buist AS, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). *Pharmacoepidemiol Drug Saf*. 2007 Jun;16(6):620-6.

Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. *Am J Transplant.* 2005 Dec;5(12):2894-900.

Funch DP, Ko HH, Travasso J, Brady J, Kew CE, 2nd, Nalesnik MA, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. *Transplantation.* 2005 Nov 15;80(9):1174-80.

Rybicki BA, **Amend KL,** Maliarik MJ, Iannuzzi MC. Photocopier exposure and risk of sarcoidosis in African-American sibs. *Sarcoidosis Vasc Diffuse Lung Dis.* 2004 Mar;21(1):49-55.

Kucera GP, Rybicki BA, **Kirkey KL,** Coon SW, Major ML, Maliarik MJ, et al. Occupational risk factors for sarcoidosis in African-American siblings. *Chest.* 2003;123(5):1527-35.

Loughlin JE, Cole JA, **Rothman KJ,** Johnson ES. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. *Ann Allergy Asthma Immunol.* 2002 Mar;88(3):319-25.

Choi HK, Merkel PA, **Walker AM,** Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. *Arthritis Rheum.* 2000 Feb;43(2):405-13.

Infection

Wong HL, Hu M, Zhou CK, Lloyd P, **Amend KL,** Beachler D, Secora A, McMahill-Walraven CN, Lu Y, Wu Y, **Ogilvie, RP,** Reich C, Djibo DA, Wan Z, **Seeger JD,** Akhtar S, Jiao Y, Chillarige Y, Do R, Hornberger J, Obidi J, Forshee R, Shoaibi A, Anderson SA. Risk of Myocarditis/ Pericarditis Following COVID-19 mRNA Vaccination in the United States: A Cohort Study in Claims Databases. *Lancet.* 2022 Jun 11;399(10342):2191-2199.

Liang C, Ogilvie RP, Doherty MC, Clifford CR, Chomistek AK, Gately RV, Song JN, Enger C, Seeger JD, Lin N, **Wang FT.** Trends in COVID-19 Patient Characteristics in a Large Electronic Health Record Database in the United States. In press at *PLOS ONE.*

Chomistek AK, Liang C, Doherty MC, Clifford CR, Ogilvie RP, Gately RV, Song JN, Enger C, Lin N.D., **Wang FT, Seeger JD.** Predictors of Critical Care, Mechanical Ventilation, and Mortality among Hospitalized Patients with COVID-19 in an Electronic Health Record Database. *BMC Infectious Diseases.* 2022 Apr;22(1):413.

Baker MA, Jankosky C, Yih K, Gruber S, Li L, Cocoros NM, Lipowicz H, Coronel-Moreno C, Feibelman S, **Lin N,** et al. The risk of febrile seizures following influenza and 13-valent pneumococcal conjugate vaccines. *Vaccine.* 2020 Feb 24; 38(9):2166-2171.

Mast TC, **Wang FT,** Su S, **Seeger JD.** Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States. *Pediatr Infect Dis J.* 2015 Jun;34(6):615-20.

McCarthy NL, Gee J, **Lin ND, Thyagarajan V,** Pan Y, Su S, et al. Evaluating the safety of influenza vaccine using a claims-based health system. *Vaccine.* 2013 Dec 5;31(50):5975-82.

Wang FT, Mast TC, Glass RJ, Loughlin J, **Seeger JD.** Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. *Pediatr Infect Dis J.* 2013 Mar;32(3):278-83.

Thyagarajan V, Norman H, Alexander KA, Napalkov P, **Enger C.** Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. *Semin Arthritis Rheum.* 2012 Dec;42(3):223-33.

Brown JS, Moore KM, Braun MM, **Ziyadeh N, Chan KA,** Lee GM, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. *Med Care.* 2009 Dec;47(12):1251-7.

Velentgas P, Bohn RL, Brown JS, **Chan KA,** Gladowski P, **Holick CN,** et al. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. *Pharmacoepidemiol Drug Saf.* 2008 Dec;17(12):1226-34.

Dore DD, DiBello JR, Lapane KL. Telithromycin use and spontaneous reports of hepatotoxicity. *Drug Saf.* 2007;30(8):697-703.

Johannes CB, Ziyadeh N, Seeger JD, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. *Drug Saf.* 2007;30(8):705-13.

Nordstrom BL, Norman HS, Dube TJ, Wilcox MA, Walker AM. Identification of abacavir hypersensitivity reaction in health care claims data. *Pharmacoepidemiol Drug Saf.* 2007 Mar;16(3):289-96.

Seeger JD, West WA, Fife D, Noel GJ, Johnson LN, **Walker AM.** Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. *Pharmacoepidemiol Drug Saf.* 2006 Nov;15(11):784-92.

Funch DP, Walker AM, Schneider G, Ziyadeh NJ, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. *Am J Transplant.* 2005 Dec;5(12):2894-900.

Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. *Curr Med Res Opin.* 2005 May;21(5):761-8.

Turnbull BR, Zoutman DE, Lam M. Evaluation of hospital and patient factors that influence the effective administration of surgical antimicrobial prophylaxis. *Infect Control Hosp Epidemiol.* 2005 May;26(5):478-85.

Nordstrom BL, Oh K, Sacks ST, L'Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. *Antivir Ther.* 2004 Apr;9(2):187-95.

Enger C, Nordstrom BL, Thakrar B, Sacks S, **Rothman KJ.** Health outcomes among patients receiving oseltamivir. *Pharmacoepidemiol Drug Saf.* 2004 Apr;13(4):227-37.

Bisson G, Gross R, Miller V, Weller I, **Walker A**, Arlett P, et al. Monitoring of long-term toxicities of HIV treatments: an international perspective. *AIDS*. 2003 Nov 21;17(17):2407-17.

Loughlin J, Poulivos N, Napalkov P, Wegmuller Y, Monto AS. A study of influenza and influenza-related complications among children in a large U.S. health insurance plan database. *Pharmacoeconomics*. 2003 Mar;21(4):273-83.

Funch DP, Brady J, Ko HH, Dreyer NA, **Walker AM**. Methods and objectives of a large U.S. multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. *Recent Results Cancer Res*. 2002;159:81-8.

Loughlin JE, Alfredson TD, Ajene AN, Cole JA, Cook SE, Rosenberg DM, et al. Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. *Clin Ther*. 2002 Nov;24(11):1786-99.

Cole JA, **Loughlin JE**, Ajene AN, Rosenberg DM, Cook SE, **Walker AM**. The effect of zanamivir treatment on influenza complications: a retrospective cohort study. *Clin Ther*. 2002 Nov;24(11):1824-39.

Werneck GL, Costa CH, **Walker AM**, David JR, Wand M, Maguire JH. The urban spread of visceral leishmaniasis: clues from spatial analysis. *Epidemiology*. 2002 May;13(3):364-7.

Irwin DE, Weatherby LB, Huang WY, Rosenberg DM, Cook SF, **Walker AM**. Impact of patient characteristics on the risk of influenza/ILI-related complications. *BMC Health Serv Res*. 2001;1:8.

Internal medicine

Mortimer KM, Bartels DB, Hartmann N, Capapey J, **Yang J**, **Gately R**, **Enger C**. Characterizing health outcomes in idiopathic pulmonary fibrosis using U.S. health claims data. *Respiration*. 2020;99(2):108-118.

Cocoros NM, Haynes K, Her Q, Cosgrove A, Dee E, **Lin ND**, et al. Identification of potential look-alike/sound-alike medication errors in the Sentinel System. *Pharmacoepidemiol Drug Saf*. 2019 Oct 22;28(10):1405-1410.

Hoffman V, Xue F, **Ezzy SM**, Yusuf A, Green E, Eisele O, Kurth T, **Seeger JD**. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine receiving prophylactic treatments: An observational cohort study. *Cephalalgia*. 2019 Oct;39(12):1544-1559. 2019 Jun 13.

Green CA, Perrin NA, Hazlehurst B, Janoff SL, DeVeaugh-Geiss A, Carrell DS, Grijalva CG, **Liang C**, **Enger CL**, Coplan PM. Identifying and classifying opioid-related overdoses: A validation study. *Pharmacoepidemiol Drug Saf*. 2019 Aug;28(8):1127-1137.

Cooper AL, **Dore DD**, Kazis LE, Mor V, Trivedi AN. Predictors of high-risk prescribing among elderly Medicare Advantage beneficiaries. *Am J Manag Care*. 2014 Oct 1;20(10):e469-78.

Cooper AL, Kazis LE, **Dore DD**, Mor V, Trivedi AN. Underreporting high-risk prescribing among Medicare Advantage plans: a cross-sectional analysis. *Ann Intern Med*. 2013 Oct 1;159(7):456-62.

Dore DD. A day in the life of a corporate retail pharmacist. *Ann Intern Med*. 2013 Sept 3;159(5):366-7.

Enger C, Younus M, Petronis KR, Mo J, **Gately R**, **Seeger JD**. The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey. *Pharmacoepidemiol Drug Saf*. 2013 Jul;22(7):705-15.

Berry SD, Lee Y, Cai S, **Dore DD**. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. *JAMA Intern Med*. 2013 May 13;173(9):754-61.

Thyagarajan V, **Norman H**, Alexander KA, Napalkov P, **Enger C**. Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. *Semin Arthritis Rheum*. 2012 Dec;42(3):223-33.

Eng PM, Mast TC, **Loughlin J**, **Clifford CR**, **Wong J**, **Seeger JD**. Incidence of intussusception among infants in a large commercially insured population in the United States. *Pediatr Infect Dis J*. 2012 Mar;31(3):287-91.

Wei JT, Miner MM, Steers WD, Rosen RC, Seftel AD, Pasta DJ, **Carman WJ**, et al. Benign prostatic hyperplasia evaluation and management by urologists and primary care physicians: practice patterns from the observational BPH registry. *J Urol*. 2011 Sep;186(3):971-6.

Enger C, Bennett D, Dawson KL, Aivado MA, Theodore D, **McAfee AT**. Hepatobiliary laboratory abnormalities among patients with chronic or persistent immune thrombocytopenia (ITP). *Ann Hepatol*. 2011 Apr-Jun;10(2):188-95.

Castellsague J, **Holick CN**, **Hoffman CC**, Gimeno V, Stang MR, Perez-Gutthann S. Risk of upper gastrointestinal complications associated with cyclooxygenase-2 selective and nonselective nonsteroidal antiinflammatory drugs. *Pharmacotherapy*. 2009 Dec;29(12):1397-407.

Dosa DM, **Dore DD**, Mor V, Teno JM. Frequency of long-acting opioid analgesic initiation in opioid-naive nursing home residents. *J Pain Symptom Manage*. 2009 Oct;38(4):515-21.

Johannes CB, **Ziyadeh N**, **Seeger JD**, Tucker E, Reiter C, Faich G. Incidence of allergic reactions associated with antibacterial use in a large, managed care organisation. *Drug Saf*. 2007;30(8):705-13.

Bravata DM, Smith-Spangler C, Sundaram V, Gienger AL, **Lin N**, Lewis R, et al. Using pedometers to increase physical activity and improve health: a systematic review. *JAMA*. 2007 Nov 21;298(19):2296-304.

Lapane KL, Quilliam BJ, **Dore DD**. Roadblock on the health IT superhighway: e-prescribing and the Controlled Substances Act. *J Opioid Manag*. 2007 Jul-Aug;3(4):181-4.

Seeger JD, **West WA**, Fife D, Noel GJ, Johnson LN, **Walker AM**. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. *Pharmacoepidemiol Drug Saf*. 2006 Nov;15(11):784-92.

Velentgas P, **West W**, Cannuscio CC, Watson DJ, **Walker AM**. Cardiovascular risk of selective cyclooxygenase-2 inhibitors and other non-aspirin non-steroidal anti-inflammatory medications. *Pharmacoepidemiol Drug Saf*. 2006 Sep;15(9):641-52.

Zavras AI, Zhu S. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? *J Oral Maxillofac Surg.* 2006 Jun;64(6):917-23.

McAfee AT, Ming EE, Seeger JD, Quinn SG, Ng EW, Danielson JD, et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48,000 initiators of statin therapy. *Pharmacoepidemiol Drug Saf.* 2006 Jul;15(7):444-53.

Sands BE, Duh MS, Cali C, Ajene A, Bohn RL, Miller D, et al. Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. *Pharmacoepidemiol Drug Saf.* 2006 Jan;15(1):47-56.

Turnbull BR, Zoutman DE, Lam M. Evaluation of hospital and patient factors that influence the effective administration of surgical antimicrobial prophylaxis. *Infect Control Hosp Epidemiol.* 2005 May;26(5):478-85.

Eng PM, Kawachi I, Fitzmaurice G, Rimm EB. Effects of marital transitions on changes in dietary and other health behaviours in U.S. male health professionals. *J Epidemiol Community Health.* 2005 Jan;59(1):56-62.

Velentgas P, Cole JA, Mo J, Sikes CR, **Walker AM.** Severe vascular events in migraine patients. *Headache.* 2004 Jul-Aug;44(7):642-51.

Nordstrom BL, Oh K, Sacks ST, L'Italien GJ. Skin reactions in patients with influenza treated with oseltamivir: a retrospective cohort study. *Antivir Ther.* 2004 Apr;9(2):187-95.

Enger C, Nordstrom BL, Thakrar B, Sacks S, Rothman KJ. Health outcomes among patients receiving oseltamivir. *Pharmacoepidemiol Drug Saf.* 2004 Apr;13(4):227-37.

Loughlin JE, Cole JA, Dodd SL, Schein JR, Thornhill JC, Walker AM. Comparison of resource utilization by patients treated with transdermal fentanyl and long-acting oral opioids for nonmalignant pain. *Pain Med.* 2002 Mar;3(1):47-55.

Reynolds RF, **Walker AM, Obermeyer CM, Rahman O, Guilbert D.** Discontinuation of postmenopausal hormone therapy in a Massachusetts HMO. *J Clin Epidemiol.* 2001 Oct;54(10):1056-64.

Schneeweiss S, Maclure M, **Walker AM, Grootendorst P, Soumerai SB.** On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. *Health Policy.* 2001 Feb;55(2):97-109.

Wang PS, **Walker A, Tsuang M, Orav EJ, Levin R, Avorn J.** Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. *J Clin Epidemiol.* 2000 Jun;53(6):571-8.

Methodology and signal detection

Chomistek AK, Phiri K, Doherty MC, Calderbank JF, Chiuve SE, Hinman-McIlroy B, Snabes MC, Enger C, Seeger JD. Development and Validation of ICD-10-CM-based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant Outcomes. *Drug Saf.* 2023 Feb;46(2):209-222.

Franklin JM, Platt R, Dreyer NA, London AJ, Simon GE, Watanabe JH, Horberg M, Hernandez A, Califf RM. When can nonrandomized studies support valid inference regarding effectiveness or safety of new medical treatments? *Clinical Pharmacology and Therapeutics,* 2022 Jan; 111(1):108-15

Loughlin AM, Chiuve SE, Reznor G, Doherty M, Missmer SA, Chomistek AK, Enger C. Method used to identify adenomyosis and potentially undiagnosed adenomyosis in a large, U.S. electronic health record database. *Pharmacoepidemiol and Drug Saf.* 2021 Dec;30(12):1675-1686.

Stevens L, Spangler L, **Yochum, L, Ding, Y, Wang, FT.** Assessment of a claims-based ICD-9 and ICD-10 medication-related osteonecrosis of the jaw algorithm in the United States. *Clinical Epidemiology,* 2021 Oct;2021(13): 1019-1026.

Seeger JD, Davis KJ, Iannacone MR, Zhou W, Dreyer N, Winterstein AG, Santanello N, Gertz B, Berlin JA. Methods for external control groups for single arm trials or long-term uncontrolled extensions to randomized clinical trials. *Pharmacoepidemiol Drug Saf.* 2020 Nov;29(11):1382-1392.

Lockhart CM, McDermott CL, Felix T, **Lin ND, Cziraky MJ, Mendelsohn AB,** et al. Barriers and facilitators to conducting high-quality, large-scale safety and comparative effectiveness research: the BBCIC experience. *Pharmacoepidemiol Drug Saf.* 2020 Jul 15;29(7):811-813.

Seeger JD, Nunes A, Loughlin AM. Using real-world evidence research to extend clinical trials in diabetes: An example with implications for the future. *Diabetes Obes Metab.* 2020 Apr;22 Suppl 3(Suppl 3):35-44.

Green CA, Perrin NA, Hazlehurst B, Janoff SL, DeVeaugh-Geiss A, Carrell DS, Grijalva CG, **Liang C, Enger CL, Coplan PM.** Identifying and classifying opioid-related overdoses: A validation study. *Pharmacoepidemiol Drug Saf.* 2019 Aug;28(8):1127-1137.

Loughlin AM, Lin N, Abler V, Carroll B. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. *PLoS One.* 2019 Jun 4;14(6):e0216044.

Brandenburg NA, Phillips S, Wells KE, Woodcroft KJ, **Amend KL, Enger C,** et al. Validating an algorithm for multiple myeloma based on administrative data using a SEER tumor registry and medical record review. *Pharmacoepidemiol Drug Saf.* 2019 Feb;28(2):256-263.

Cocoros NM, Pokorney SD, Haynes H, Garcia C, Al-Khalidi HR, Al-Khatib SM, Archdeacon P, Goldsack JC, Harkins T, **Lin ND,** et al. FDA-Catalyst-Using FDA's Sentinel Initiative for large scale pragmatic randomized trials: Approach and lessons learned during the planning phase of the first trial. *Clin Trials.* 2019 Feb;16(1):90-97.

Amend KL, Younus M, Petronis KR, Mo J, Seeger JD, Gately R, et al. Assessment of risk evaluation and mitigation strategies (REMS) for varenicline (Chantix): A multistage patient survey. *Pharmacoepidemiol Drug Saf.* 2018 Mar;27(3):253-262.

Funch D, Ross D, Gardstein BM, Norman HS, Sanders LA, Major-Pedersen A, et al. Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies. *BMC Health Serv Res.* 2017;17:330.

- Hoffman V**, Everage NJ, Quinlan SC, **Skerry K**, Esposito D, Praet N, et al. Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured U.S. populations. *Pharmacoepidemiol Drug Saf*. 2016 Dec;25(12):1465-9.
- Harrison MS, Eckert LO, Cutland C, Gravett M, Harper DM, McClure EM, **Nunes A**, et al. Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2016 Dec 1;34(49):6093-101.
- Quinn JA, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, Kissou A, Wittke F, Das M, **Nunes T**, et al. Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. *Vaccine*. 2016 Dec 1;34(49):6047-56.
- Liang C, Seeger JD, Dore DD**. Implications of immortal person-time when outcomes are nonfatal. *Ann Epidemiol*. 2016 Mar;26(3):212-7.
- Liang C, Li L**, Fraser CD, Ko A, Corzo D, **Enger C**, et al. The treatment patterns, efficacy, and safety of nab[®]-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. *BMC Cancer*. 2015;15:1019.
- Zarotsky V, Huang MY, **Carman W**, Morgentaler A, Singhal PK, Coffin D, et al. Systematic literature review of the risk factors, comorbidities, and consequences of hypogonadism in men. *Andrology*. 2014 Nov;2(6):819-34.
- Hoffman V**, Xue F, **Gardstein B, Skerry K**, Critchlow CW, **Enger C**. Development and evaluation of an algorithm to identify users of Prolia[®] during the early postmarketing period using health insurance claims data. *Pharmacoepidemiol Drug Saf*. 2014 Sept;23(9):993-8.
- McCarthy NL, Gee J, **Lin ND, Thyagarajan V**, Pan Y, Su S, et al. Evaluating the safety of influenza vaccine using a claims-based health system. *Vaccine*. 2013 Dec 5;31(50):5975-82.
- Thyagarajan V, Su S**, Gee J, Duffy J, McCarthy NL, **Chan KA**, et al. Identification of seizures among adults and children following influenza vaccination using health insurance claims data. *Vaccine*. 2013 Dec 5;31(50):5997-6002.
- Berry SD, **Dore DD**. Understanding drug effects in older people: the role of pharmacology – reply. *JAMA Intern Med*. 2013 Nov 11;173(20):1930-1.
- Dore DD**, Swaminathan S, Gutman R, Trivedi AN, Mor V. Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes. *J Clin Epidemiol*. 2013 Aug;66(8 Suppl):S42-50.
- Funch D, Holick C, Velentgas P, Clifford R**, Wahl PM, McMahill-Walraven C, et al. Algorithms for identification of Guillain-Barre Syndrome among adolescents in claims databases. *Vaccine*. 2013 Apr 12;31(16):2075-9.
- Dore DD, Seeger JD, Chan KA**. Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. *Ther Adv Drug Saf*. 2012 Aug;3(4):157-64.
- Dore DD, Liang C, Ziyadeh N, Norman H, Bayliss M, Seeger JD**. Linkage of routinely collected oncology clinical data with health insurance claims data – an example with aromatase inhibitors, tamoxifen, and all-cause mortality. *Pharmacoepidemiol Drug Saf*. 2012 May;21 Suppl 2:29-36.
- Wang S, Linkletter C, Maclure M, **Dore D**, Mor V, Buka S, et al. Future cases as present controls to adjust for exposure trend bias in case-only studies. *Epidemiology*. 2011 Jul;22(4):568-74.
- Enger C, Gately R**, Ming EE, Niemcryk SJ, Williams L, **McAfee AT**. Pharmacoepidemiology safety study of fibrate and statin concomitant therapy. *Am J Cardiol*. 2010 Dec;106(11):1594-601.
- Brown JS, Moore KM, Braun MM, **Ziyadeh N, Chan KA**, Lee GM, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. *Med Care*. 2009 Dec;47(12):1251-7.
- Platt R, Wilson M, **Chan KA**, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network – improving the evidence of medical-product safety. *N Engl J Med*. 2009 Aug 13;361(7):645-7.
- Dore DD, Seeger JD, Arnold Chan K**. Use of a claims-based active drug safety surveillance system to assess the risk of acute pancreatitis with exenatide or sitagliptin compared to metformin or glyburide. *Curr Med Res Opin*. 2009 Apr;25(4):1019-27.
- Velentgas P, Bohn RL, Brown JS, **Chan KA**, Gladowski P, **Holick CN**, et al. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. *Pharmacoepidemiol Drug Saf*. 2008 Dec;17(12):1226-34.
- Eng PM, Seeger JD, Loughlin J, Clifford CR, Mentor S, Walker AM**. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. *Pharmacoepidemiol Drug Saf*. 2008 Mar;17(3):297-305.
- Seeger JD, Kurth T, Walker AM**. Use of propensity score technique to account for exposure-related covariates: an example and lesson. *Med Care*. 2007 Oct;45(10 Supl 2):S143-8.
- Nordstrom BL, Norman HS, Dube TJ, Wilcox MA, Walker AM**. Identification of abacavir hypersensitivity reaction in health care claims data. *Pharmacoepidemiol Drug Saf*. 2007 Mar;16(3):289-96.
- Johansson S, Ming EE, Wallander MA, Rodriguez LA, Herings RM, Goettsch WG, **McAfee AT, Walker AM**. Rosuvastatin safety: a comprehensive, international pharmacoepidemiology programme. *Pharmacoepidemiol Drug Saf*. 2006;15(7):454-61.
- Walker A**. More lawyers. More bureaucrats. Less information on drug safety (Commentary). *Pharmacoepidemiol Drug Saf*. 2006 Jun;15:394-5.
- Sands BE, Duh MS, Cali C, Ajene A**, Bohn RL, **Miller D**, et al. Algorithms to identify colonic ischemia, complications of constipation and irritable bowel syndrome in medical claims data: development and validation. *Pharmacoepidemiol Drug Saf*. 2006 Jan;15(1):47-56.

Friedman DS, **Nordstrom B**, Mozaffari E, Quigley HA. Variations in treatment among adult-onset open-angle glaucoma patients. *Ophthalmology*. 2005 Sep;112(9):1494-9.

Seeger JD, Williams PL, **Walker AM**. An application of propensity score matching using claims data. *Pharmacoepidemiol Drug Saf*. 2005 Jul;14(7):465-76.

Bisson G, Gross R, Miller V, Weller I, **Walker A**, Arlett P, et al. Monitoring of long-term toxicities of HIV treatments: an international perspective. *AIDS*. 2003 Nov 21;17(17):2407-17.

Rubio-Stipek M, Fitzmaurice G, Murphy J, **Walker A**. The use of multiple informants in identifying the risk factors of depressive and disruptive disorders – are they interchangeable? *Soc Psychiatry Psychiatr Epidemiol*. 2003 Feb;38(2):51-8.

Funch DP, Brady J, Ko HH, Dreyer NA, **Walker AM**. Methods and objectives of a large U.S. multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. *Recent Results Cancer Res*. 2002;159:81-8.

Seeger JD. Causal structures for evaluating statin class effects. *Ann Pharmacother*. 2002 Dec;36(12):1961-5.

Rubio-Stipek M, **Walker A**, Murphy J, Fitzmaurice G. Dimensional measures of psychopathology. The probability of being classified with a psychiatric disorder using empirically derived symptom scales. *Soc Psychiatry Psychiatr Epidemiol*. 2002 Dec;37(12):553-60.

Reynolds RF, Obermeyer CM, **Walker AM**, Guilbert D. The role of treatment intentions and concerns about side effects in women's decision to discontinue postmenopausal hormone therapy. *Maturitas*. 2002 Nov 20;43(3):183-94.

Hurley CR, Mishra A, Cantor SE, Nelson M, **Walker AM**. A 'real-world' analysis of persistence on and adherence to glipizide GITS, glipizide IR and glibenclamide in managed care among patients with type 2 diabetes mellitus. *Clin Drug Investig*. 2002 Sep;22(9):575-84.

Schneeweiss S, Maclure M, Soumerai SB, **Walker AM**, Glynn RJ. Quasi-experimental longitudinal designs to evaluate drug benefit policy changes with low policy compliance. *J Clin Epidemiol*. 2002 Aug;55(8):833-41.

Werneck GL, Costa CH, **Walker AM**, David JR, Wand M, Maguire JH. The urban spread of visceral leishmaniasis: clues from spatial analysis. *Epidemiology*. 2002 May;13(3):364-7.

Rothman KJ, Ray W. Should cases with a 'known' cause of their disease be excluded from study? (commentary). *Pharmacoepidemiol Drug Saf*. 2002 Jan-Feb;11(1):11-4.

Walker AM, Wise RP. Precautions for proactive surveillance. *Pharmacoepidemiol Drug Saf*. 2002 Jan-Feb;11(1):17-20.

Schneeweiss S, **Seeger JD**, Maclure M, Wang PS, Avorn J, Glynn RJ. Performance of comorbidity scores to control for confounding in epidemiologic studies using claims data. *Am J Epidemiol*. 2001 Nov 1;154(9):854-64.

Walker AM. Pattern recognition in health insurance claims databases. *Pharmacoepidemiol Drug Saf*. 2001 Aug-Sep;10(5):393-7.

Wang PS, **Walker AM**, Tsuang MT, Orav EJ, Levin R, Avorn J. Finding incident breast cancer cases through U.S. claims data and a state cancer registry. *Cancer Causes Control*. 2001 Apr;12(3):257-65.

Schneeweiss S, Maclure M, **Walker AM**, Grootendorst P, Soumerai SB. On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. *Health Policy*. 2001 Feb;55(2):97-109.

Choi HK, **Seeger JD**, Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. *Arthritis Rheum*. 2000 Oct;43(10):2316-27.

Wang PS, **Walker A**, Tsuang M, Orav EJ, Levin R, Avorn J. Strategies for improving comorbidity measures based on Medicare and Medicaid claims data. *J Clin Epidemiol*. 2000 Jun;53(6):571-8.

Musculoskeletal

Hoffman V, Xue F, Gardstein B, **Skerry K**, Critchlow CW, **Enger C**. Assessment of off-label use of denosumab 60 mg injection during the early postmarketing period using health insurance claims data. *Osteoporos Int*. 2016 Apr;27(4):1653-8.

Hoffman V, Xue F, **Gardstein B**, **Skerry K**, Critchlow CW, **Enger C**. Development and evaluation of an algorithm to identify users of Prolia® during the early postmarketing period using health insurance claims data. *Pharmacoepidemiol Drug Saf*. 2014 Sept;23(9):993-8.

Berry SD, Lee Y, Cai S, **Dore DD**. Nonbenzodiazepine sleep medication use and hip fractures in nursing home residents. *JAMA Intern Med*. 2013 May 13;173(9):754-61.

Amend KL, **Landon J**, **Thyagarajan V**, Niemcryk S, **McAfee A**. Incidence of hospitalized rhabdomyolysis with statin and fibrate use in an insured U.S. population. *Ann Pharmacother*. 2011 Oct;45(10):1230-9.

Dore DD, Trivedi AN, Mor V, Friedman JH, Lapane KL. Atypical antipsychotic use and risk of fracture in persons with Parkinsonism. *Mov Disord*. 2009 Oct 15;24(13):1941-8.

Seeger JD, **West WA**, Fife D, Noel GJ, Johnson LN, **Walker AM**. Achilles tendon rupture and its association with fluoroquinolone antibiotics and other potential risk factors in a managed care population. *Pharmacoepidemiol Drug Saf*. 2006 Nov;15(11):784-92.

Zavras AI, **Zhu S**. Bisphosphonates are associated with increased risk for jaw surgery in medical claims data: is it osteonecrosis? *J Oral Maxillofac Surg*. 2006 Jun;64(6):917-23.

Johannes CB, **Schneider GA**, **Dube TJ**, **Alfredson TD**, Davis KJ, **Walker AM**. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. *Chest*. 2005 Jan;127(1):89-97.

Neurology

Chomistek AK, Hoffman V, Urman R, Gill KS, **Ezzy SM**, **Zhou L**, Park AS, Loop B, Lopez-Leon S, McAllister P, **Wang FT**. Inpatient Constipation Among Migraine Patients Prescribed Anti-Calcitonin Gene-related Peptide Monoclonal Antibodies and Standard of Care Antiepileptic Drugs: A Retrospective Cohort Study in a United States Electronic Health Record Database. *Pain Ther*. 2022 Dec;11(4):1415-1437.

Baker MA, Jankosky C, Yih K, Gruber S, Li L, Cocoros NM, Lipowicz H, Coronel-Moreno C, Feibelman S, **Lin N**, et al. The Risk of Febrile Seizures Following Influenza and 13-Valent Pneumococcal Conjugate Vaccines. *Vaccine*. 2020 Feb 24; 38(9):2166-2171.

Hoffman V, Xue F, **Ezzy SM**, Yusuf A, Green E, Eisele O, Kurth T, **Seeger JD**. Risk of cardiovascular and cerebrovascular events and mortality in patients with migraine receiving prophylactic treatments: An observational cohort study. *Cephalalgia*. 2019 Oct;39(12):1544-1559. 2019 Oct;39(12):1544-1559.

Eum KD, **Wang FT**, Schwartz J, Hersh CP, Kelsey K, Wright RO, et al. Modifying roles of glutathione S-transferase polymorphisms on the association between cumulative lead exposure and cognitive function. *Neurotoxicology*. 2013 Dec;39:65-71.

Thyagarajan V, **Su S**, Gee J, Duffy J, McCarthy NL, **Chan KA**, et al. Identification of seizures among adults and children following influenza vaccination using health insurance claims data. *Vaccine*. 2013 Dec 5;31(50):5997-6002.

Enger C, Younus M, Petronis KR, Mo J, **Gately R**, **Seeger JD**. The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey. *Pharmacoepidemiol Drug Saf*. 2013 Jul;22(7):705-15.

Funch D, **Holick C**, **Velentgas P**, **Clifford CR**, Wahl PM, McMahl-Walraven C, et al. Algorithms for identification of Guillain-Barre Syndrome among adolescents in claims databases. *Vaccine*. 2013 Apr 12;31(16):2075-9.

McAfee AT, **Landon J**, Jones M, Bangs ME, Acharya N, Hornbuckle K, et al. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications. *Pharmacoepidemiol Drug Saf*. 2013 Apr;22(4):386-93.

Velentgas P, Amato AA, Bohn RL, **Chan KA**, Cochrane T, **Funch DP**, et al. Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. *Pharmacoepidemiol Drug Saf*. 2012 Dec;21(12):1350-8.

Pellock JM, **Carman WJ**, **Thyagarajan V**, Daniels T, Morris DL, D'Cruz O. Efficacy of antiepileptic drugs in adults predicts efficacy in children: a systematic review. *Neurology*. 2012 Oct 2;79(14):1482-9.

Green MW, **Seeger JD**, Peterson C, Bhattacharyya A. Utilization of topiramate during pregnancy and risk of birth defects. *Headache*. 2012 Jul-Aug;52(7):1070-84.

Carman WJ, **Su S**, Cook SF, Wurzelmann JI, **McAfee A**. Coronary heart disease outcomes among chronic opioid and cyclooxygenase-2 users compared with a general population cohort. *Pharmacoepidemiol Drug Saf*. 2011 Jul;20(7):754-62.

Amend KL, **Turnbull B**, Foskett N, Napalkov P, **Kurth T**, **Seeger J**. Incidence of progressive multifocal leukoencephalopathy in patients without HIV. *Neurology*. 2010 Oct;75(15):1326-32.

Funch D, **Norman H**, **Wong J**, Bennett R, Hillier J, Al-Sabbagh A, et al. Adherence to recommended dosing and monitoring for mitoxantrone in patients with multiple sclerosis: a healthcare claims database study supplemented with medical records – the RETRO study. *Pharmacoepidemiol Drug Saf*. 2010 May;19(5):448-56.

Holick CN, **Turnbull BR**, Jones ME, **Chaudhry S**, Bangs ME, **Seeger JD**. Atomoxetine and cerebrovascular outcomes in adults. *J Clin Psychopharmacol*. 2009 Oct;29(5):453-60.

Dore DD, Trivedi AN, Mor V, Friedman JH, Lapane KL. Atypical antipsychotic use and risk of fracture in persons with Parkinsonism. *Mov Disord*. 2009 Oct 15;24(13):1941-8.

Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, **Dore DD**. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. *Am J Geriatr Pharmacother*. 2009 Apr;7(2):74-83.

McAfee AT, Holdridge KC, **Johannes CB**, Hornbuckle K, **Walker AM**. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. *Curr Drug Saf*. 2008 May;3(2):123-31.

Wang FT, Hu H, Schwartz J, Weuve J, Spiro AS, Sparrow D, et al. Modifying effects of the HFE polymorphisms on the association between lead burden and cognitive decline. *Environ Health Perspect*. 2007 Aug;115(8):1210-5.

McAfee AT, Chilcott KE, **Johannes CB**, Hornbuckle K, Hauser WA, **Walker AM**. The incidence of first provoked and unprovoked seizure in pediatric patients with and without psychiatric diagnoses. *Epilepsia*. 2007 Jun;48(6):1075-82.

Eng PM, **Turnbull BR**, Cook SF, Davidson JE, Kurth T, **Seeger JD**. Characteristics and antecedents of progressive multifocal leukoencephalopathy in an insured population. *Neurology*. 2006 Sep;67(5):884-6.

Velentgas P, Cole JA, Mo J, Sikes CR, **Walker AM**. Severe vascular events in migraine patients. *Headache*. 2004 Jul-Aug;44(7):642-51.

Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, **Walker AM**. Hepatitis B vaccination and the risk of multiple sclerosis. *N Engl J Med*. 2001 Feb 1;344(5):327-32.

Oncology

Nunes AP, **Liang C**, Gradishar WJ, Dalvi T, Lewis J, Jones N, Green E, **Doherty M**, **Seeger JD**. U.S. prevalence of endocrine therapy-naïve locally advanced or metastatic breast cancer. *Curr Oncol*. 2019 Apr;26(2):e180-e187.

Liang C, **Bertoia ML**, **Ding Y**, **Clifford CR**, Qiao Q, **Gagne JJ**, **Dore DD**. Exenatide use and incidence of pancreatic and thyroid cancer: A retrospective cohort study. *Diabetes Obes Metab*. 2019 Apr;21(4):1037-1042.

- Funch D, Mortimer K, Ziyadeh NJ, Seeger JD, Li L, Norman H, Major-Pedersen A, Bosch-Traberg H, Gydesen H, Dore DD.** Liraglutide use and evaluation of pancreatic outcomes in a U.S. commercially insured population. *Diabetes Obes Metab.* 2019;1-12.
- Funch D, Mortimer K, Li L, Norman H, Major-Pedersen A, Olsen AH, Kaltoft MS, Dore DD.** Is there an association between liraglutide use and female breast cancer in a real-world setting? *Diabetes Metab Syndr Obes.* 2018 Nov;11:791-806.
- Funch D, Ross D, Gardstein BM, Norman HS, Sanders LA, Major-Pedersen A, et al.** Performance of claims-based algorithms for identifying incident thyroid cancer in commercial health plan enrollees receiving antidiabetic drug therapies. *BMC Health Serv Res.* 2017;17:330.
- Liang C, Li L, Fraser CD, Ko A, Corzo D, Enger C, et al.** The treatment patterns, efficacy, and safety of nab[®]-paclitaxel for the treatment of metastatic breast cancer in the United States: results from health insurance claims analysis. *BMC Cancer.* 2015;15:1019.
- Funch D, Gydesen H, Tornoe K, Major-Pedersen A, Chan KA.** A prospective, claims-based assessment of the risk of pancreatitis and pancreatic cancer with liraglutide compared to other antidiabetic drugs. *Diabetes Obes Metab.* 2014 Mar;16(3):273-5.
- Thyagarajan V, Norman H, Alexander KA, Napalkov P, Enger C.** Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. *Semin Arthritis Rheum.* 2012 Dec;42(3):223-33.
- Dore DD, Seeger JD, Chan KA.** Incidence of health insurance claims for thyroid neoplasm and pancreatic malignancy in association with exenatide: signal refinement using active safety surveillance. *Ther Adv Drug Saf.* 2012 Aug;3(4):157-64.
- Dore DD, Liang C, Ziyadeh N, Norman H, Bayliss M, Seeger JD.** Linkage of routinely collected oncology clinical data with health insurance claims data – an example with aromatase inhibitors, tamoxifen, and all-cause mortality. *Pharmacoepidemiol Drug Saf.* 2012 May;21 Suppl 2:29-36.
- Nunes AP, Lapane KL, Weinstock MA, Group VT.** Association between non-steroidal anti-inflammatory drugs and keratinocyte carcinomas of the skin among participants in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. *Pharmacoepidemiol Drug Saf.* 2011 Sept;20(9):922-9.
- Ziyadeh N, Fife D, Walker AM, Wilkinson GS, Seeger JD.** A matched cohort study of the risk of cancer in users of becaplermin. *Adv Skin Wound Care.* 2011 Jan;24(1):31-9.
- Schneeweiss S, **Doherty M, Zhu S, Funch D, Schlienger RG, Fernandez-Vidaurre C, et al.** Topical treatments with pimecrolimus, tacrolimus and medium- to high-potency corticosteroids, and risk of lymphoma. *Dermatology.* 2009;219(1):7-21.
- Pelletier SJ, Fu S, **Thyagarajan V, Romero-Marrero C, Batheja MJ, Punch JD, et al.** An intention-to-treat analysis of liver transplantation for hepatocellular carcinoma using organ procurement transplant network data. *Liver Transpl.* 2009 Aug;15(8):859-68.
- Dore DD, Lapane KL, Trivedi AN, Mor V, Weinstock MA.** Association between statin use and risk for keratinocyte carcinoma in the veterans affairs topical tretinoin chemoprevention trial. *Ann Intern Med.* 2009 Jan 6;150(1):9-18.
- Amend K, Choi J, Ambrosone C.** Role of genetic variability in breast cancer treatment outcomes. In: Leyland-Jones B, editor. *Pharmacogenetics of breast cancer: Towards the individualization of therapy.* 1st ed. New York, NY: Informa Healthcare USA, Inc.;2008:25-43.
- Flick ED, Habel LA, **Chan KA, Van Den Eeden SK, Quinn VP, Haque R, et al.** Statin use and risk of prostate cancer in the California Men's Health Study cohort. *Cancer Epidemiol Biomarkers Prev.* 2007 Nov;16(11):2218-25.
- Amend K, Hicks D, Ambrosone CB.** Breast cancer in African-American women: differences in tumor biology from European-American women. *Cancer Res.* 2006 Sep 1;66(17):8327-30.
- Funch DP, Ko HH, Travasso J, Brady J, Kew CE, 2nd, Nalesnik MA, et al.** Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. *Transplantation.* 2005 Nov 15;80(9):1174-80.
- Amend KL, Elder JT, Tomsho LP, Bonner JD, Johnson TM, Schwartz J, et al.** EGF gene polymorphism and the risk of incident primary melanoma. *Cancer Res.* 2004 Apr;64(8):2668-72.
- Funch DP, Brady J, Ko HH, Dreyer NA, Walker AM.** Methods and objectives of a large U.S. multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. *Recent Results Cancer Res.* 2002;159:81-8.
- Wang PS, **Walker AM, Tsuang MT, Orav EJ, Glynn RJ, Levin R, et al.** Dopamine antagonists and the development of breast cancer. *Arch Gen Psychiatry.* 2002 Dec;59(12):1147-54.
- Kaye JA, Meier CR, **Walker AM, Jick H.** Statin use, hyperlipidaemia, and the risk of breast cancer. *Br J Cancer.* 2002 May 6;86(9):1436-9.
- Walker AM, Maxim LD, Utell M.** Risk analysis for mortality from respiratory tumors in a cohort of refractory ceramic fiber workers. *Regul Toxicol Pharmacol.* 2002 Feb;35(1):95-104.
- Wang PS, **Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J.** Antidepressant use and the risk of breast cancer: a non-association. *J Clin Epidemiol.* 2001 Jul;54(7):728-34.
- Hernandez-Diaz S, Werler MM, **Walker AM, Mitchell AA.** Neural tube defects in relation to use of folic acid antagonists during pregnancy. *Am J Epidemiol.* 2001 May 15;153(10):961-8.
- Wang PS, **Walker AM, Tsuang MT, Orav EJ, Levin R, Avorn J.** Finding incident breast cancer cases through U.S. claims data and a state cancer registry. *Cancer Causes Control.* 2001 Apr;12(3):257-65.
- Hernandez-Diaz S, Werler MM, **Walker AM, Mitchell AA.** Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med.* 2000 Nov 30;343(22):1608-14.

Ophthalmology

Everage NJ, Bai Y, Loop B, Volkova N, **Liu N, Enger C**. Diagnosed cataracts in patients with cystic fibrosis in a United States administrative database. *Ophthalmic Genet*. 2017 Dec;38(6):527-532.

Velentgas P, Sheffield R, **Nordstrom B**, Johnson E, Do T, **Mentor SM**, et al. Persistence with medications in glaucoma management, hypertension, and dyslipidemia. *J Pharm Technol*. 2007;23(4):221-31.104.

Friedman DS, **Nordstrom B**, Mozaffari E, Quigley HA. Variations in treatment among adult-onset open-angle glaucoma patients. *Ophthalmology*. 2005 Sep;112(9):1494-9.

Friedman DS, **Nordstrom B**, Mozaffari E, Quigley HA. Glaucoma management among individuals enrolled in a single comprehensive insurance plan. *Ophthalmology*. 2005 Sep;112(9):1500-4.

Nordstrom BL, Friedman DS, Mozaffari E, Quigley HA, **Walker AM**. Persistence and adherence with topical glaucoma therapy. *Am J Ophthalmol*. 2005 Oct;140(4):598-606.

Duh MS, **Walker AM**, Lindmark B, Laties AM. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. *Ann Allergy Asthma Immunol*. 2000 Nov;85(5):356-61.

Psychiatric

Bulik CM, **Bertoia ML**, Lu M, **Seeger JD**, Spalding WM. Suicidality risk among adults with binge-eating disorder. *Suicide and Life-Threatening Behaviors*. 2021; 51(5): 897-906.

Spalding WM, **Bertoia ML**, Bulik CM, **Seeger JD**. Treatment characteristics among patients with binge-eating disorder: an electronic health record analysis. *Postgraduate Medicine*. [in press].

Loughlin AM, **Lin N**, Abler V, Carroll B. Tardive dyskinesia among patients using antipsychotic medications in customary clinical care in the United States. *PLoS One*. 2019 Jun 4;14(6):e0216044.

Lin ND, **Norman H**, Regev A, Perahia DG, Li H, Chang CL, et al. Hepatic outcomes among adults taking duloxetine: a retrospective cohort study in a U.S. health care claims database. *BMC Gastroenterol*. 2015 Oct 14;15:134.

Enger C, Jones ME, Kryzhanovskaya L, **Doherty M**, **McAfee AT**. Risk of developing diabetes and dyslipidemia among adolescents with bipolar disorder or schizophrenia. *Int J Adolesc Med Health*. 2013;25(1):3-11.

Nunes AP, Phipps MG. Postpartum depression in adolescent and adult mothers: comparing prenatal risk factors and predictive models. *Matern Child Health J*. 2013 Aug;17(6):1071-9.

Enger C, Younus M, Petronis KR, Mo J, **Gately R**, **Seeger JD**. The effectiveness of varenicline medication guide for conveying safety information to patients: a REMS assessment survey. *Pharmacoepidemiol Drug Saf*. 2013 Jul;22(7):705-15.

McAfee AT, **Landon J**, Jones M, Bangs ME, Acharya N, Hornbuckle K, et al. A cohort study of the risk of seizures in a pediatric population treated with atomoxetine or stimulant medications. *Pharmacoepidemiol Drug Saf*. 2013 Apr;22(4):386-93.

Thyagarajan V, **Clifford CR**, Wurst KE, Ephross SA, **Seeger JD**. Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. *Pharmacoepidemiol Drug Saf*. 2012 Nov;21(11):1240-2.

Xue F, Strombom I, **Turnbull B**, **Zhu S**, **Seeger J**. Treatment with duloxetine in adults and the incidence of cardiovascular events. *J Clin Psychopharmacol*. 2012 Feb;32(1):23-30.

Wang S, Linkletter C, **Dore D**, Mor V, Buka S, Maclure M. Age, antipsychotics, and the risk of ischemic stroke in the Veterans Health Administration. *Stroke*. 2012 Jan;43(1):28-31.

Habel LA, Cooper WO, Sox CM, **Chan KA**, Fireman BH, Arbogast PG, et al. ADHD medications and risk of serious cardiovascular events in young and middle-aged adults. *JAMA*. 2011;306(24):2673-83.

Cooper WO, Habel LA, Sox CM, **Chan KA**, Arbogast PG, Cheatham TC, et al. ADHD drugs and serious cardiovascular events in children and young adults. *N Engl J Med*. 2011;365(20):1896-904.

Xue F, Strombom I, **Turnbull B**, **Zhu S**, **Seeger JD**. Duloxetine for depression and the incidence of hepatic events in adults. *J Clin Psychopharmacol*. 2011 Aug;31(4):517-22.

Holick CN, **Turnbull BR**, Jones ME, **Chaudhry S**, Bangs ME, **Seeger JD**. Atomoxetine and cerebrovascular outcomes in adults. *J Clin Psychopharmacol*. 2009 Oct;29(5):453-60.

Dore DD, Trivedi AN, Mor V, Friedman JH, Lapane KL. Atypical antipsychotic use and risk of fracture in persons with Parkinsonism. *Mov Disord*. 2009 Oct 15;24(13):1941-8.

Daiello LA, Ott BR, Lapane KL, Reinert SE, Machan JT, **Dore DD**. Effect of discontinuing cholinesterase inhibitor therapy on behavioral and mood symptoms in nursing home patients with dementia. *Am J Geriatr Pharmacother*. 2009 Apr;7(2):74-83.

McAfee AT, Holdridge KC, **Johannes CB**, Hornbuckle K, **Walker AM**. The effect of pharmacotherapy for attention deficit hyperactivity disorder on risk of seizures in pediatric patients as assessed in an insurance claims database. *Curr Drug Saf*. 2008 May;3(2):123-31.

Strombom I, Wernicke JF, **Seeger J**, D'Souza DN, Acharya N. Hepatic effects of duloxetine-III: analysis of hepatic events using external data sources. *Curr Drug Saf*. 2008 May;3(2):154-62.

Cole JA, Ephross SA, Cosmatos IS, **Walker AM**. Paroxetine in the first trimester and the prevalence of congenital malformations. *Pharmacoepidemiol Drug Saf*. 2007 Oct;16(10):1075-85.

McAfee AT, Chilcott KE, **Johannes CB**, Hornbuckle K, Hauser WA, **Walker AM**. The incidence of first provoked and unprovoked seizure in pediatric patients with and without psychiatric diagnoses. *Epilepsia*. 2007 Jun;48(6):1075-82.

Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, **Walker AM**. Bupropion in pregnancy and the prevalence of congenital malformations. *Pharmacoepidemiol Drug Saf*. 2007 May;16(5):474-84.

Enger C, Weatherby L, Reynolds RF, Glasser DB, **Walker AM**. Serious cardiovascular events and mortality among patients with schizophrenia. *J Nerv Ment Dis*. 2004 Jan;192(1):19-27.

Rubio-Stipeć M, Fitzmaurice G, Murphy J, **Walker A**. The use of multiple informants in identifying the risk factors of depressive and disruptive disorders – are they interchangeable? *Soc Psychiatry Psychiatr Epidemiol*. 2003 Feb;38(2):51-8.

Eng PM, Fitzmaurice G, Kubzansky LD, Rimm EB, Kawachi I. Anger expression and risk of stroke and coronary heart disease among male health professionals. *Psychosom Med*. 2003 Jan-Feb;65(1):100-10.

Eng PM, Rimm EB, Fitzmaurice G, Kawachi I. Social ties and change in social ties in relation to subsequent total and cause-specific mortality and coronary heart disease incidence in men. *Am J Epidemiol*. 2002;155(8):700-9.

Wang PS, **Walker AM**, Tsuang MT, Orav EJ, Glynn RJ, Levin R, et al. Dopamine antagonists and the development of breast cancer. *Arch Gen Psychiatry*. 2002 Dec;59(12):1147-54.

Rubio-Stipeć M, **Walker A**, Murphy J, Fitzmaurice G. Dimensional measures of psychopathology. The probability of being classified with a psychiatric disorder using empirically derived symptom scales. *Soc Psychiatry Psychiatr Epidemiol*. 2002 Dec;37(12):553-60.

Wang PS, **Walker AM**, Tsuang MT, Orav EJ, Levin R, Avorn J. Antidepressant use and the risk of breast cancer: a non-association. *J Clin Epidemiol*. 2001 Jul;54(7):728-34.

Reynolds RF, Obermeyer CM, **Walker AM**, Guilbert D. Side effects and sociobehavioral factors associated with the discontinuation of hormone therapy in a Massachusetts health maintenance organization. *Menopause*. 2001 May-Jun;8(3):189-99.

Renal

Blanchette CM, **Liang C**, Lubeck DP, Newsome B, Rossetti S, **Gu X**, et al. Progression of autosomal dominant kidney disease: measurement of the stage transitions of chronic kidney disease. *Drugs Context*. 2015 Apr 17;4:212275.

Dore DD, Swaminathan S, Gutman R, Trivedi AN, Mor V. Different analyses estimate different parameters of the effect of erythropoietin stimulating agents on survival in end-stage renal disease: a comparison of payment policy analysis, instrumental variables, and multiple imputation of potential outcomes. *J Clin Epidemiol*. 2013 Aug;66(8 Suppl):S42-50.

Walker AM, **Schneider G**, **Yeaw J**, **Nordstrom B**, Robbins S, Pettitt D. Anemia as a predictor of cardiovascular events in patients with elevated serum creatinine. *J Am Soc Nephrol*. 2006;17(8):2293-8.

Funch DP, **Walker AM**, **Schneider G**, **Ziyadeh NJ**, Pescovitz MD. Ganciclovir and acyclovir reduce the risk of post-transplant lymphoproliferative disorder in renal transplant recipients. *Am J Transplant*. 2005 Dec;5(12):2894-900.

Funch DP, **Ko HH**, **Travasso J**, **Brady J**, Kew CE, 2nd, Nalesnik MA, et al. Posttransplant lymphoproliferative disorder among renal transplant patients in relation to the use of mycophenolate mofetil. *Transplantation*. 2005 Nov 15;80(9):1174-80.

Kurth T, Glynn RJ, **Walker AM**, Rexrode KM, Buring JE, Stampfer MJ, et al. Analgesic use and change in kidney function in apparently healthy men. *Am J Kidney Dis*. 2003 Aug;42(2):234-44.

Funch DP, Brady J, Ko HH, Dreyer NA, **Walker AM**. Methods and objectives of a large U.S. multicenter case-control study of post-transplant lymphoproliferative disorder in renal transplant patients. *Recent Results Cancer Res*. 2002;159:81-8.

Reproductive and pregnancy

Hughes KC, Herring TA, **Song J**, **Gately R**, Nowak LM, **Ogilvie RP**, Simon K, Bhuyan PK, Kyrgiou M, **Seeger JD**. Cervical HSIL Burden and Standard of Care Treatment and Effectiveness in the United States, 2008-2018: the EACH-WOMAN Project. *J Low Genit Tract Dis*. 2023 Apr 1;27(2):105-112.

Chomistek AK, Phiri K, **Doherty MC**, **Calderbank JF**, Chiuve SE, Hinman-McIlroy B, Snabes MC, Enger C, **Seeger JD**. Development and Validation of ICD-10-CM-based Algorithms for Date of Last Menstrual Period, Pregnancy Outcomes, and Infant Outcomes. *Drug Saf*. 2023 Feb;46(2):209-222.

Kaplan S, **Bertoia ML**, Lass A, **Wang FT**, Evans A, Dhanda S, Roy D, **Seeger JD**. Delayed pregnancy detection and return to fertility with extended levonorgestrel-containing oral contraceptives: A real world setting cohort. *Contraception*, 2022 Jan; 105:26-32. *Pharmacoepidemiol Drug Saf*. 2022 Jun 17 [Online ahead of print].

Bertoia ML, Phiri K, **Clifford CR**, **Doherty M**, **Zhou L**, Wang LT, Bertoia NA, **Wang FT**, **Seeger JD**. Identification of pregnancies and infants within a United States commercial healthcare administrative claims database. *Pharmacoepidemiology and Drug Saf*. [in press].

Loughlin AM, Chiuve SE, **Reznor G**, **Doherty M**, Missmer SA, **Chomistek AK**, **Enger C**. Method used to identify adenomyosis and potentially undiagnosed adenomyosis in a large, U.S. electronic health record database. *Pharmacoepidemiology and Drug Saf*. 2021 Dec;30(12):1675-1686.

Kaplan S, **Bertoia ML**, **Wang FT**, **Zhou L**, Lass A, Evans A, Dhanda S, Roy D, **Seeger JD**. Long-term safety of extended levonorgestrel-containing oral contraceptives in the United States. *Contraception*, 2022 Jan; 105:26-32.

Carman WJ, Accortt NA, Anthony MS, Iles J, **Enger C**. Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. *Pharmacoepidemiol Drug Saf*. 2017 Sep;26(9):1109-18.

Wyszynski DF, **Carman WJ**, Cantor AB, Graham JM, Jr., Kunz LH, Slavotinek AM, et al. Pregnancy and birth outcomes among women with idiopathic thrombocytopenic purpura. *J Pregnancy*. 2016;2016:8297407.

Harrison MS, Eckert LO, Cutland C, Gravett M, Harper DM, McClure EM, **Nunes A**, et al. Pathways to preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2016 Dec 1;34(49):6093-101.

Quinn JA, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, Kissou A, Wittke F, Das M, **Nunes T**, et al. Preterm birth: Case definition & guidelines for data collection, analysis, and presentation of immunisation safety data. *Vaccine*. 2016 Dec 1;34(49):6047-56.

Danilack VA, **Nunes AP**, Phipps MG. Unexpected complications of low-risk pregnancies in the United States. *Am J Obstet Gynecol*. 2015 Jun;212(6):809.e1-6.

Tennis P, **Chan KA**, Curkendall SM, Li DK, Mines D, Peterson C, et al. Topiramate use during pregnancy and major congenital malformations in multiple populations. *Birth Defects Res A Clin Mol Teratol*. 2015 Apr;103(4):269-75.

Nunes AP, Phipps MG. Postpartum depression in adolescent and adult mothers: comparing prenatal risk factors and predictive models. *Matern Child Health J*. 2013 Aug;17(6):1071-9.

Phipps MG, **Nunes AP**. Assessing pregnancy intention and associated risks in pregnant adolescents. *Matern Child Health J*. 2012 Dec;16(9):1820-7.

Thyagarajan V, **Robin Clifford CR**, Wurst KE, Ephross SA, **Seeger JD**. Bupropion therapy in pregnancy and the occurrence of cardiovascular malformations in infants. *Pharmacoepidemiol Drug Saf*. 2012 Nov;21(11):1240-2.

Green MW, **Seeger JD**, Peterson C, Bhattacharyya A. Utilization of topiramate during pregnancy and risk of birth defects. *Headache*. 2012 Jul-Aug;52(7):1070-84.

Phipps MG, Salak JR, **Nunes AP**, Rosengard C. Career aspirations and pregnancy intentions in pregnant teens. *J Pediatr Adolesc Gynecol*. 2011 Apr;24(2):e11-5.

Dore DD, **Norman H**, **Loughlin J**, **Seeger JD**. Extended case-control study results on thromboembolic outcomes among transdermal contraceptive users. *Contraception*. 2010 May;81(5):408-13.

Dore DD, **Norman H**, **Seeger JD**. Eligibility criteria in venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. *Obstet Gynecol*. 2009 Jul;114(1):175.

Loughlin J, **Seeger JD**, **Eng PM**, **Foegh M**, **Clifford CR**, **Cutone J**, et al. Risk of hyperkalemia in women taking ethinylestradiol/drospirenone and other oral contraceptives. *Contraception*. 2008 Nov;78(5):377-83.

Eng PM, **Seeger JD**, **Loughlin J**, **Clifford CR**, **Mentor S**, **Walker AM**. Supplementary data collection with case-cohort analysis to address potential confounding in a cohort study of thromboembolism in oral contraceptive initiators matched on claims-based propensity scores. *Pharmacoepidemiol Drug Saf*. 2008 Mar;17(3):297-305.

Cole JA, Ephross SA, Cosmatos IS, **Walker AM**. Paroxetine in the first trimester and the prevalence of congenital malformations. *Pharmacoepidemiol Drug Saf*. 2007 Oct;16(10):1075-85.

Seeger JD, **Loughlin J**, **Eng PM**, **Clifford CR**, **Cutone J**, **Walker AM**. Risk of thromboembolism in women taking ethinylestradiol/drospirenone and other oral contraceptives. *Obstet Gynecol*. 2007 Sep;110(3):587-93.

Cole JA, Modell JG, Haight BR, Cosmatos IS, Stoler JM, **Walker AM**. Bupropion in pregnancy and the prevalence of congenital malformations. *Pharmacoepidemiol Drug Saf*. 2007 May;16(5):474-84.

Mona Eng P, **Seeger JD**, **Loughlin J**, **Oh K**, **Walker AM**. Serum potassium monitoring for users of ethinyl estradiol/drospirenone taking medications predisposing to hyperkalemia: physician compliance and survey of knowledge and attitudes. *Contraception*. 2007 Feb;75(2):101-7.

Cole JA, **Norman H**, **Doherty M**, **Walker AM**. Venous thromboembolism, myocardial infarction, and stroke among transdermal contraceptive system users. *Obstet Gynecol*. 2007 Feb;109(2 Pt 1):339-46.

Seeger JD, **Lanza LL**, **West WA**, Fernandez C, Rivero E. Pregnancy and pregnancy outcome among women with inflammatory skin diseases. *Dermatology*. 2007;214(1):32-9.

Kieffer EC, Tabaei BP, **Carman WJ**, Nolan GH, Guzman JR, Herman WH. The influence of maternal weight and glucose tolerance on infant birthweight in Latino mother-infant pairs. *Am J Public Health*. 2006 Dec;96(12):2201-8.

Rothman KJ, **Funch DP**, Alfredson T, Brady J, Dreyer NA. Randomized field trial of vaginal douching, pelvic inflammatory disease and pregnancy. *Epidemiology*. 2003 May;14(3):340-8.

Hernandez-Diaz S, Werler MM, **Walker AM**, Mitchell AA. Neural tube defects in relation to use of folic acid antagonists during pregnancy. *Am J Epidemiol*. 2001 May 15;153(10):961-8.

Hernandez-Diaz S, Werler MM, **Walker AM**, Mitchell AA. Folic acid antagonists during pregnancy and the risk of birth defects. *N Engl J Med*. 2000 Nov 30;343(22):1608-14.

Respiratory

Mortimer KM, Bartels DB, Hartmann N, Capapey J, **Yang J**, **Gately R**, **Enger C**. Characterizing health outcomes in idiopathic pulmonary fibrosis using U.S. health claims data. *Respiration*. 2020;99(2):108-118.

Mortimer K, Hartmann N, **Chan C**, **Norman H**, Wallace L, **Enger C**. Characterizing idiopathic pulmonary fibrosis patients using U.S. Medicare-advantage health plan claims data. *BMC Pulmonary Medicine*. 2019 Jan;19(1):11.

Everage NJ, Bai Y, Loop B, Volkova N, **Liu N**, **Enger C**. Diagnosed cataracts in patients with cystic fibrosis in a United States administrative database. *Ophthalmic Genet*. 2017 Dec;38(6):527-532.

McCarthy NL, Gee J, **Lin ND**, **Thyagarajan V**, Pan Y, Su S, et al. Evaluating the safety of influenza vaccine using a claims-based health system. *Vaccine*. 2013 Dec 5;31(50):5975-82.

Harrold LR, **Patterson MK**, Andrade SE, **Dube T**, Go AS, Buist AS, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). *Pharmacoepidemiol Drug Saf*. 2007 Jun;16(6):620-6.

Nordstrom BL, Sung I, Suter P, Szneke P. Risk of pneumonia and other complications of influenza-like illness in patients treated with oseltamivir. *Curr Med Res Opin.* 2005 May;21(5):761-8.

Johannes CB, Schneider GA, Dube TJ, Alfredson TD, Davis KJ, **Walker AM.** The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. *Chest.* 2005 Jan;127(1):89-97.

Enger C, Nordstrom BL, Thakrar B, Sacks S, **Rothman KJ.** Health outcomes among patients receiving oseltamivir. *Pharmacoepidemiol Drug Saf.* 2004 Apr;13(4):227-37.

Rybicki BA, **Amend KL,** Maliarik MJ, Iannuzzi MC. Photocopier exposure and risk of sarcoidosis in African-American sibs. *Sarcoidosis Vasc Diffuse Lung Dis.* 2004 Mar;21(1):49-55.

Kucera GP, Rybicki BA, **Kirkey KL,** Coon SW, Major ML, Maliarik MJ, et al. Occupational risk factors for sarcoidosis in African-American siblings. *Chest.* 2003;123(5):1527-35.

Rothman KJ, Wentworth CE 3rd. Mortality of cystic fibrosis patients treated with tobramycin solution for inhalation. *Epidemiology.* 2003;14(1):55-9.

Loughlin J, Poullos N, Napalkov P, Wegmuller Y, Monto AS. A study of influenza and influenza-related complications among children in a large U.S. health insurance plan database. *Pharmacoeconomics.* 2003 Mar;21(4):273-83.

Loughlin JE, Alfredson TD, Ajene AN, Cole JA, Cook SE, Rosenberg DM, et al. Risk for respiratory events in a cohort of patients receiving inhaled zanamivir: a retrospective study. *Clin Ther.* 2002 Nov;24(11):1786-99.

Loughlin JE, Cole JA, **Rothman KJ,** Johnson ES. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. *Ann Allergy Asthma Immunol.* 2002 Mar;88(3):319-25.

Walker AM, Maxim LD, Utell M. Risk analysis for mortality from respiratory tumors in a cohort of refractory ceramic fiber workers. *Regul Toxicol Pharmacol.* 2002 Feb;35(1):95-104.

Irwin DE, Weatherby LB, Huang WY, Rosenberg DM, Cook SF, **Walker AM.** Impact of patient characteristics on the risk of influenza/ILI-related complications. *BMC Health Serv Res.* 2001;1:8.

Duh MS, **Walker AM,** Lindmark B, Laties AM. Association between intraocular pressure and budesonide inhalation therapy in asthmatic patients. *Ann Allergy Asthma Immunol.* 2000 Nov;85(5):356-61.

Rich S, Rubin L, **Walker AM,** Schneeweiss S, Abenham L. Anorexigens and pulmonary hypertension in the United States: results from the surveillance of North American pulmonary hypertension. *Chest.* 2000 Mar;117(3):870-4.

Rheumatology

Ziyadeh NJ, Geldhof A, Noël W, Otero-Lobato M, Esslinger S, Chakravarty SD, Wang Y, **Seeger JD.** Post-approval safety surveillance study of golimumab in the treatment of rheumatic disease using a United States health care claims database. *Clinical Drug Investigation.* 2020 Nov;40(11):1021-1040.

Carman WJ, Accortt NA, Anthony MS, Iles J, **Enger C.** Pregnancy and infant outcomes including major congenital malformations among women with chronic inflammatory arthritis or psoriasis, with and without etanercept use. *Pharmacoepidemiol Drug Saf.* 2017 Sep;26(9):1109-18.

Thyagarajan V, Norman H, Alexander KA, Napalkov P, **Enger C.** Risk of mortality, fatal infection, and fatal malignancy related to use of anti-tumor necrosis factor-alpha biologics by rheumatoid arthritis patients. *Semin Arthritis Rheum.* 2012 Dec;42(3):223-33.

Wilcox MA, McAfee AT. Empirically derived subgroups in rheumatoid arthritis: association with single-nucleotide polymorphisms on chromosome 6. *BMC Proc.* 2007;1 Suppl 1:S20.

Wilcox MA, Li Z, Tapper W, Browning S, Curtin K, Ding J, et al. Genetic association with rheumatoid arthritis-genetic analysis workshop 15: summary of contributions from group 2. *Genet Epidemiol.* 2007;31 Suppl 1:S12-21.

Harrold LR, **Patterson MK,** Andrade SE, **Dube T,** Go AS, Buist AS, et al. Asthma drug use and the development of Churg-Strauss syndrome (CSS). *Pharmacoepidemiol Drug Saf.* 2007 Jun;16(6):620-6.

Choi HK, **Seeger JD,** Kuntz KM. Effects of rofecoxib and naproxen on life expectancy among patients with rheumatoid arthritis: a decision analysis. *Am J Med.* 2004 May;116(9):621-9.

Choi HK, Hernan MA, **Seeger JD,** Robins JM, Wolfe F. Methotrexate and mortality in patients with rheumatoid arthritis: a prospective study. *Lancet.* 2002 Apr 6;359(9313):1173-7.

Loughlin JE, Cole JA, **Rothman KJ,** Johnson ES. Prevalence of serious eosinophilia and incidence of Churg-Strauss syndrome in a cohort of asthma patients. *Ann Allergy Asthma Immunol.* 2002 Mar;88(3):319-25.

Choi HK, **Seeger JD,** Kuntz KM. A cost-effectiveness analysis of treatment options for patients with methotrexate-resistant rheumatoid arthritis. *Arthritis Rheum.* 2000 Oct;43(10):2316-27.

Choi HK, Merkel PA, **Walker AM,** Niles JL. Drug-associated antineutrophil cytoplasmic antibody-positive vasculitis: prevalence among patients with high titers of antimyeloperoxidase antibodies. *Arthritis Rheum.* 2000 Feb;43(2):405-13.

Vaccines

Hu M, Wong HL, Feng Y, Lloyd PC, Smith ER, **Amend KL,** Kline A, Beachler DC, Gruber JF, Mitra M, **Seeger JD,** Harris C, Secora A, Obidi J, Wang J, **Song J,** McMahill-Walraven CN, Reich C, McEvoy R, Do R, Chillarige Y, **Clifford CR,** Cooper DD, Shoaibi A, Forshee R, Anderson SA. Results of safety monitoring of BNT162b2 (Pfizer-BioNTech) COVID-19 vaccine U.S. children aged 5-17 years: a cohort study of vaccine safety. Safety of the BNT162b2 COVID-19 Vaccine in Children Aged 5 to 17 Years. *JAMA Pediatr.* Published online May 22, 2023.

Schneider KL, **Bell EJ**, Zhou CK, Grace Yang, Lloyd PC, Clarke TC, **Wilkinson M**, Myers EE, **Amend KL**, **Seeger JD**, Chillarige Y, Forshee R, Shoaibi A, Anderson SA, Wong HL. Immunization Information Systems to Improve Ascertainment of COVID-19 Vaccinations for Claims-based Vaccine Safety and Effectiveness Studies. *JAMA Network Open*. 2023;6(5):e2313512.5.

Moll K, Lufkin B, Fingar KR, Zhou CK, Tworowski E, Shi C, Hobbi S, Hu M, Sheng M, McCarty J, Shangguan S, Burrell T, Chillarige Y, Beers J, Saunders-Hastings P, Edwards K, Muthuri S, Black S, Kelman J, Reich C, **Amend KL**, Djibo A, Beachler D, **Ogilvie RP**, Secora A, McMahonill-Walraven CN, **Seeger JD**, Lloyd P, Thompson D, Dimova R, MaCurdy T, Obidi J, Anderson S, Forshee R, Wong HL, Shoaibi A. Background Rates of Adverse Events of Special Interest for COVID-19 Vaccine Safety Monitoring in the United States, 2019-2020. *Vaccine*. 2023; 41(2):333-353.

Seeger JD, **Amend KL**, **Turnbull BR**, **Zhou L**, Marks MA, Velicer C, Saddier P. Incident autoimmune conditions among males receiving quadrivalent human papillomavirus vaccine in the United States. *Vaccine*. 2022, S0264-410X(22)01307-X.

Lloyd P, Hu M, Wong HL, Shoaibi A, Zhou CK, Lo AC, **Amend KL**, Beachler D, McMahonill-Walraven C, Smith E, **Seeger JD**, Secora A, Djibo DA, Obidi J, Feng Y, **Song J**, Reich C, Harris C, Akhtar S, **Clifford CR**, Selvam N, Pigoga J, Jiao Y, Chillarige Y, MaCurdy T, Forshee R, Anderson S. Near Real-Time Surveillance of Safety Outcomes in U.S. COVID-19 Vaccine Recipients aged 12 to 64 years *Vaccine*. 2022; 40(45):6481-6488.

Amend KL, Turnbull B, Zhou L, Marks MA, Velicer C, Saddier P, Seeger JD. Safety of 4-valent human papillomavirus vaccine in males: a large observational postmarketing study. *Human Vaccines & Immunotherapeutics*. 2022. Jun 17; 2073750. Advance online publication.

Wong HL, Hu M, Zhou CK, Lloyd P, **Amend KL**, Beachler D, Secora A, McMahonill-Walraven CN, Lu Y, Wu Y, **Ogilvie, RP**, Reich C, Djibo DA, Wan Z, **Seeger JD**, Akhtar S, Jiao Y, Chillarige Y, Do R, Hornberger J, Obidi J, Forshee R, Shoaibi A, Anderson SA. Risk of Myocarditis/ Pericarditis Following COVID-19 mRNA Vaccination in the United States: A Cohort Study in Claims Databases. *Lancet*. 2022. Jun 11;399(10342):2191-2199.

Amend KL, Turnbull B, Zhou L, Marks MA, Velicer C, Saddier P, Seeger JD. Vaccine initiation and 3-dose series completion of 4vHPV vaccine among US insured males. 2012-2016. *Vaccine*. 2022. Jan 28; 40(4), 682-688.

Baker MA, Jankosky C, Yih WK, Gruber S, Li L, Cocoros NM, Lipowicz H, Coronel-Moreno C, DeLuccia S, **Lin ND**, et al. The Risk of Febrile Seizures Following Influenza and 13-Valent Pneumococcal Conjugate Vaccines. *Vaccine*. 2020 Feb 24; 38(9):2166-2171.

Hoffman V, Abu-Elyazeed R, **Enger C**, Esposito DB, **Doherty MC**, Quinlan SC, et al. Safety study of live, oral human rotavirus vaccine: a cohort study in United States health Insurance Plans. *Hum Vaccin Immunother*. 2018 Mar;13:1-9.

Hoffman V, Everage NJ, Quinlan SC, **Skerry K**, Esposito D, Praet N, et al. Validation of current procedural terminology codes for rotavirus vaccination among infants in two commercially insured U.S. populations. *Pharmacoepidemiol Drug Saf*. 2016 Dec;25(12):1465-9.

Harrison MS, Eckert LO, Cutland C, Gravett M, Harper DM, McClure EM, **Nunes A**, et al. Pathways to preterm birth: case definition and guidelines for data collection, analysis, and presentation of immunization safety data. *Vaccine*. 2016 Dec 1;34(49):6093-101.

Quinn JA, Munoz FM, Gonik B, Frau L, Cutland C, Mallett-Moore T, Kissou A, Wittke F, Das M, **Nunes T**, et al. Preterm birth: Case definition and guidelines for data collection, analysis, and presentation of immunisation safety data. *Vaccine*. 2016 Dec 1;34(49):6047-56.

Yih WK, Greene SK, Zichittella L, Kulldorff M, Baker MA, de Jong JL, Gil-Prieto R, Griffin MR, Jin R, **Lin ND**, et al. Evaluation of the risk of venous thromboembolism after quadrivalent human papillomavirus vaccination among U.S. females. *Vaccine*. 2016 Jan 2;34(1):172-8.

Mast TC, **Wang FT**, Su S, **Seeger JD**. Evidence of herd immunity and sustained impact of rotavirus vaccination on the reduction of rotavirus-related medical encounters among infants from 2006 through 2011 in the United States. *Pediatr Infect Dis J*. 2015 Jun;34(6):615-20.

McCarthy NL, Gee J, **Lin ND**, **Thyagarajan V**, Pan Y, Su S, et al. Evaluating the safety of influenza vaccine using a claims-based health system. *Vaccine*. 2013 Dec 5;31(50):5975-82.

Thyagarajan V, **Su S**, Gee J, Duffy J, McCarthy NL, **Chan KA**, et al. Identification of seizures among adults and children following influenza vaccination using health insurance claims data. *Vaccine*. 2013 Dec 5;31(50):5997-6002.

Funch D, **Holick C**, **Velentgas P**, **Clifford CR**, Wahl PM, McMahonill-Walraven C, et al. Algorithms for identification of Guillain-Barre Syndrome among adolescents in claims databases. *Vaccine*. 2013 Apr 12;31(16):2075-9.

Wang FT, Mast TC, Glass RJ, Loughlin J, **Seeger JD**. Effectiveness of an incomplete RotaTeq (RV5) vaccination regimen in preventing rotavirus gastroenteritis in the United States. *Pediatr Infect Dis J*. 2013 Mar;32(3):278-83.

Velentgas P, Amato AA, Bohn RL, **Chan KA**, Cochrane T, **Funch DP**, et al. Risk of Guillain-Barre syndrome after meningococcal conjugate vaccination. *Pharmacoepidemiol Drug Saf*. 2012 Dec;21(12):1350-8.

Dore DD, **Turnbull BR**, **Seeger JD**. Vaccine discontinuation and switching following regulatory interventions in response to rotavirus vaccine contamination with porcine circovirus DNA fragments. *Pharmacoepidemiol Drug Saf*. 2012 Apr;21(4):415-9.

Loughlin J, Mast TC, **Doherty MC**, **Wang FT**, **Wong J**, **Seeger JD**. Postmarketing evaluation of the short-term safety of the pentavalent rotavirus vaccine. *Pediatr Infect Dis J*. 2012 Mar;31(3):292-6.

Lin ND, Kleinman K, Chan KA, Soumerai S, Mehta J, Mulooly JP, et al. Multiple vaccinations and the risk of medically attended fever. *Vaccine*. 2010 Jun 7;28(25):4169-74.

Wang FT, Mast TC, **Glass RJ**, **Loughlin J**, **Seeger JD**. Effectiveness of the pentavalent rotavirus vaccine in preventing gastroenteritis in the United States. *Pediatrics*. 2010 Feb;125(2):e208-13.

Brown JS, Moore KM, Braun MM, **Ziyadeh N, Chan KA**, Lee GM, et al. Active influenza vaccine safety surveillance: potential within a healthcare claims environment. *Med Care*. 2009 Dec;47(12):1251-7.

Loughlin J, Wang FT, El Khoury A, **Doherty M**, Mast TC, **Seeger JD**. Adherence to the recommended pentavalent rotavirus vaccine administration schedule in the United States: 2006-2007. *Pediatr Infect Dis J*. 2009 Jul;28(7):667-8.

Velentgas P, Bohn RL, Brown JS, **Chan KA**, Gladowski P, **Holick CN**, et al. A distributed research network model for post-marketing safety studies: the Meningococcal Vaccine Study. *Pharmacoepidemiol Drug Saf*. 2008 Dec;17(12):1226-34.

Lin ND, Kleinman K, Chan KA, Yu X-J, France EK, Wei F, et al. Variation in hepatitis B immunization coverage rates associated with provider practices after the temporary suspension of the birth dose. *BMC Pediatrics*. 2006 Nov;6(1):31.

Lin ND, Kleinman K, **Chan KA**, Yu XJ, France EK, Xu S, et al. Impact of the introduction of pneumococcal conjugate vaccine on immunization coverage among infants. *BMC Pediatr*. 2005 Nov;5:43.

Ascherio A, Zhang SM, Hernan MA, Olek MJ, Coplan PM, Brodovicz K, **Walker AM**. Hepatitis B vaccination and the risk of multiple sclerosis. *N Engl J Med*. 2001 Feb 1;344(5):327-32.



optum.com/epidemiology

Optum is a registered trademark of Optum, Inc. in the U.S. and other jurisdictions. All other brand or product names are the property of their respective owners. Because we are continuously improving our products and services, Optum reserves the right to change specifications without prior notice. Optum is an equal opportunity employer.

© 2023 Optum, Inc. All rights reserved. WF11597907 9/23